




BR

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ : A61K 47/00	A1	(11) International Publication Number: WO 88/ 04938 (43) International Publication Date: 14 July 1988 (14.07.88)
<p>(21) International Application Number: PCT/US87/02846</p> <p>(22) International Filing Date: 2 November 1987 (02.11.87)</p> <p>(31) Priority Application Number: 002,387</p> <p>(32) Priority Date: 12 January 1987 (12.01.87)</p> <p>(33) Priority Country: US</p> <p>(71)(72) Applicant and Inventor: RAJADHYAKSHA, Vithal, J. [US/US]; 27436 Esquina, Mission Viejo, CA 92691 (US).</p> <p>(74) Agent: HUBBARD, Grant, L.; Bank of America Building, 300 South Harbor Boulevard, Suite 805, Anaheim, CA 92805 (US).</p> <p>(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).</p>		<p>Published With international search report.</p>

(54) Title: HETEROCYCLIC COMPOUNDS FOR TRANSDERMAL USE



(I)

(57) Abstract

A method and compositions for topically administering physiologically active agents through the skin and mucous membranes of humans and animals in a transdermal device or formulation for systemic use or to the skin of humans and animals for localized use comprising applying to such skin or membrane a mixture of said physiologically active agent and a non-toxic, effective penetrating amount of penetration enhancing compound having the structural formula (I), wherein R is a saturated or unsaturated hydrocarbon group with from 5 to 19 carbon atoms; R' and R'' are hydrogen, lower alkyl, trifluoromethyl, lower hydroxylalkyl or lower alkyl ester of lower hydroxyalkyl, with the proviso that both R' and R'' are not lower hydroxyalkyl; X is O or NR₁; R₁ being hydrogen, lower alkyl, lower alkenyl, lower hydroxyalkyl or lower alkyl ester of lower hydroxyalkyl.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

Heterocyclic compounds for transdermal use

Background of the Invention

Many physiologically active agents are best applied
5 topically to obtain desirable results. Topical application, in the form of creams, lotions, gels, solutions, etc., largely avoids side effects of the agents and permits high level concentrations of the agents.

10 Some therapeutic drugs may also be administered for systemic use through the skin or other body membranes including intranasal and intravaginal application of humans and other animals, utilizing a transdermal device or formulated in a suppository or aerosol spray. For
15 some years, pharmaceutical researchers have sought an effective means of introducing drugs into the bloodstream by applying them to the unbroken skin. Among other advantages, such administration can provide a comfortable, convenient and safe way of giving many
20 drugs now taken orally or infused into veins or injected intramuscularly.

Using skin as the portal for drug entry offers unique potential, because transdermal delivery permits close control over drug absorption. For example, it
25 avoids factors that can cause unpredictable absorption from gastrointestinal tract, including: changes in acidity, motility, and food content. It also avoids initial metabolism of the drug by the liver known as the first pass effect. Thus, controlled drug entry through
30 skin can achieve a high degree of control over blood concentrations of drug.

Close control over drug concentration in blood can translate readily into safer and more comfortable treatment. When a drug's adverse effects occur at

higher concentrations than its beneficial ones, rate control can maintain the concentration that evoke only- or principally the drug's desired actions. This ability to lessen undesired drug actions can greatly
5 reduce the toxicity hazards that now restrict or prevent the use of many valuable agents.

Transdermal delivery particularly benefits patients with chronic disease. Many such patients have difficulty following regimens requiring several doses
10 daily of medications that repeatedly cause unpleasant symptoms. They find the same drugs much more acceptable when administered in transdermal system that require application infrequently - in some cases, only once or twice weekly - and reduce adverse effects.

15 Transdermal delivery is feasible for drugs effective in amounts that can pass through the skin area and that are substantially free of localized irritating or allergic effects. While these limitations may exclude some agents, many others remain eligible for
20 transdermal delivery. Moreover, their numbers will expand as pharmaceutical agents of greater potency are developed. Particularly suitable for transdermal delivery are potent drugs with only a narrow spread between their toxic and safe blood concentrations, those
25 having gastrointestinal absorption problems, those susceptible to a higher first pass liver metabolism or those requiring frequent dosing in oral or injectable form.

Transdermal therapy permits much wider use of
30 natural substances such as hormones. Often the survival times of these substances in the body are so short that they would have to be taken many times daily in ordinary dosage forms. Continuous transdermal delivery provides a practical way of giving them, and one that can mimic
35 the body's own patterns of secretion.

At present, controlled transdermal therapy appears feasible for many drugs used for a wide variety of ailments including, but not limited to, circulatory problems, hormone deficiency, respiratory ailments, and pain relief.

Percutaneous administration can have the advantage of permitting continuous administration of drug to the circulation over prolonged periods of time to obtain a uniform delivery rate and blood level of drug. Commencement and termination of drug therapy are initiated by the application and removal of the dosing devices from the skin. Uncertainties of administration through the gastrointestinal tract and the inconvenience of administration by injection are eliminated. Since a high concentration of drug never enters the body, problems of pulse entry are overcome and metabolic half-life is not a factor of controlling importance.

The greatest problems in applying physiologically active agents topically or transdermally is that the skin is an effective barrier to penetration. The epidermis of the skin has an exterior layer of dead cells called the stratum corneum which is tightly compacted and oily and which provides an effective barrier against gaseous, solid or liquid chemical agents, whether used alone or in water or in oil solutions. If a physiologically active agent penetrates the stratum corneum, it can readily pass through the basal layer of the epidermis and into the dermis.

Although the effectiveness of the stratum corneum as a barrier provides great protection, it also frustrates efforts to apply beneficial agents directly to local areas of the body. The inability of physiologically active agents to penetrate the stratum corneum prevents their effective use of treating such conditions as inflammation, acne, psoriasis, herpes

labialis, herpes genitalis, eczema, infections caused by fungi, viruses and other microorganisms, or other disorders or conditions of the skin or mucous membranes or of conditions beneath the exterior surface of the skin or mucous membranes. The stratum corneum also prevents the skin from absorbing and retaining cosmetic-type materials such as sunscreens, perfumes, mosquito repellents and the like.

Physiologically active agents may be applied to the locally affected parts of the body in the form of a solution, cream, lotion or gel utilizing the vehicle system described herein. These agents may also be delivered for systemic use utilizing the vehicle system in a transdermal patch. Vehicles such as USP cold cream, ethanol and various ointments, oils, solvents and emulsions have been used heretofore to apply physiologically active ingredients locally. Most such vehicles are not effective to carry significant amounts of physiologically active agents into and through the skin. One such vehicle is dimethyl sulfoxide, which is described in U.S. Patent No. 3,551,554.

My previous inventions disclosed in U.S. Patent Nos. 3,989,816; 3,991,203; 4,112,170; 4,316,893; 4,415,563; 4,423,040; 4,424,210; 4,444,762 describe a method for enhancing the topical administration of physiologically active agents by combining such an agent with an effective amount of a penetration enhancer and applying the combination topically to humans or animals, in the form of solution, cream, gel, lotion etc. This prior art discloses N-alkyl substituted cyclic lactams as penetration enhancers.

My related U.S. Patent 4,405,616 describes a method for administering systemically active agents through the skin or other body membranes of humans and animals, utilizing a transdermal device or formulation containing

an effective amount of a suitable membrane penetration enhancer selected from the disclosed N-alkyl substituted cyclic lactams.


My related U.S. Application, Ser. No. 783,621, filed on September 30, 1985, describes a method for enhancing topical and transdermal administration of physiologically active agents with membrane penetration enhancers selected from the alkanolic acid cyclic amides disclosed therein.

Penetration enhancers for enhancing systemic administration of therapeutic agents transdermally disclosed in the art include dodecyl pyrrolidone, dimethyl lauramide and dimethyl sulfoxide. These agents may be used prior to or concurrently with administration of the active agent, see, e.g., U.S. Patent Nos. 4,031,894; 3,996,934 and 3,921,636.

SUMMARY OF THE INVENTION

The invention relates to compositions for carrying physiologically active agents through body membranes such as skin and for retaining these agents in the body tissues and further relates to a method of administering systemically active agents through the skin or other body membranes of humans and animals, utilizing a transdermal device or formulation, containing an effective, non-toxic amount of a membrane penetration enhancer having the structural formula I:

I



wherein:

R is a saturated or unsaturated hydrocarbon group

with from 5 to 19 carbon atoms,
R' and R" are hydrogen, lower alkyl, trifluoro-
methyl, lower hydroxyalkyl or lower alkyl ester of
lower hydroxyalkyl, with the proviso that both R'
5 and R" are not lower hydroxyalkyl,
X is O or NR₁; R₁ being Hydrogen, lower alkyl,
lower alkenyl, lower hydroxyalkyl or lower alkyl
ester of lower hydroxyalkyl.

In one preferred embodiment of I, R' and R" are H;
10 R, X and R₁ being as defined. The preferred compounds
of this embodiment are:

2-(2-dodecyl)-2-oxazoline,
2-(2-methyl-2-decyl)-2-oxazoline,
2-Undecyl-2-imidazoline,
15 1-Methyl-2-heptyl-2-imidazoline,
1-Isopropyl-2-undecyl-2-imidazoline,
1-Hydroxyethyl-2-octyl-2-imidazoline, and
1-[2-(Trimethylacetoxymethyl)-2-octyl-2-imidazoline.

In another preferred embodiment of the composition
20 I, R' is Hydrogen, R" is lower alkyl or trifluoromethyl:
X and R₁ being as defined. The preferred compounds of
this embodiment are:

4-Methyl-2-(2-dodecyl)-2-oxazoline,
4-Isopropyl-2-(2-dodecyl)-2-oxazoline,
25 4-Trifluoromethyl-2-(2-dodecyl)-2-oxazoline,
4-Isopropyl-2-(2-methyl-2-decyl)-2-oxazoline,
4-Methyl-2-undecyl-2-imidazoline,
4-Isopropyl-2-undecyl-2-imidazoline,
4-t-Butyl-2-undecyl-2-imidazoline,
30 4-Trifluoromethyl-2-undecyl-2-imidazoline,
1,4-Diisopropyl-2-undecyl-2-imidazoline,
4-Methyl-1-isopropyl-2-undecyl-2-imidazoline,
4-Methyl-2-(2-dodecyl)-2-imidazoline, and
4-Methyl-2-(2-methyl-2-decyl)-2-imidazoline.

35 In yet another preferred embodiment of I, R' and R"

are lower alkyl or trifluoromethyl; R and X being as defined. The preferred compounds of this embodiment are:

- 4,4-Dimethyl-2-undecyl-2-oxazoline,
- 5 4-Methyl-4-trifluoromethyl-2-undecyl-2-oxazoline,
- 4,4-Dimethyl-2-(1-dodecen-2-yl)-2-oxazoline,
- 4-Methyl-4-trifluoromethyl-2-(1-dodecen-2-yl)-2-oxazoline,
- 4,4-Dimethyl-2-(2-dodecyl)-2-oxazoline,
- 10 4,4-Dimethyl-2-(2-methyl-2-decyl)-2-oxazoline,
- 4,4-Dimethyl-2-undecyl-2-imidazoline,
- 4-Methyl-4-t-butyl-2-undecyl-2-imidazoline,
- 4,4-Dimethyl-1-isopropyl-2-undecyl-2-imidazoline,
- 4-Methyl-1,4-diisopropyl-2-undecyl-2-imidazoline,
- 15 4,4-Dimethyl-2-(2-dodecyl)-2-imidazoline,
- 4,4-Dimethyl-1-isopropyl-2-(2-dodecyl)-2-imidazoline,
- 4,4-Dimethyl-2-(2-methyl-2-decyl)-2-imidazoline,
- 4,4-Dimethyl-1-isopropyl-2-(2-methyl-2-decyl)-2-imidazoline.

- 20 In still another preferred embodiment of I, R' is lower alkyl or trifluoromethyl and X is O; the other substituents being as defined.

The preferred compounds are:

- 4-Hydroxymethyl-4-methyl-2-undecyl-2-oxazoline,
- 25 4-Hydroxymethyl-4-trifluoromethyl-2-undecyl-2-oxazoline,
- 4-Trimethylacetoxymethyl-4-methyl-2-undecyl-2-oxazoline,
- 4-Hydroxymethyl-4-methyl-2-(2-dodecyl)-2-oxazoline,
- 4-Hydroxymethyl-4-methyl-2-(2-methyl-2-decyl)-2-oxazoline,
- 30 4-Trimethylacetoxymethyl-4-methyl-2-(2-dodecyl)-2-oxazoline, and
- 4-Trimethylacetoxymethyl-4-methyl-2-(2-methyl-2-decyl)-2-oxazoline.

- 35 It has been found that the physiologically active agents are carried through body membranes by the claimed

penetration enhancers and are retained in the body tissue when applied topically in form of a creme, gel, or lotion or absorbed systemically when applied in the form of a transdermal device or formulation, for example, as a transdermal patch, a rectal or vagina suppository, as a nasal spray or when incorporated in a vaginal sponge or tampon.

DETAILED DESCRIPTION OF THE INVENTION

Typical examples of compounds included in the foregoing formula I of this invention are the following:

1. 4-Trifluoromethyl-2-undecyl-2-oxazoline.
2. 4-Isopropyl-2-nonyl-2-oxazoline.
3. 4-Isopropyl-2-undecyl-2-oxazoline.
4. 4-t-Butyl-2-undecyl-2-oxazoline.
5. 4-Methyl-4-trifluoromethyl-2-undecyl-2-oxazoline.
6. 4-Methyl-4-isopropyl-2-undecyl-2-oxazoline.
7. 4-Methyl-4-t-butyl-2-undecyl-2-oxazoline.
8. 4-Trifluoromethyl-2-(1-dodecen-2-yl)-2-oxazoline.
9. 4,4-Dimethyl-2-(1-dodecen-2-yl)-2-oxazoline.
10. 4-methyl-4-trifluoromethyl-2-(1-dodecen-2-yl)-2-oxazoline.
11. 4-Hydroxymethyl-4-trifluoromethyl-2-undecyl-2-oxazoline.
12. 4-Trimethylacetoxymethyl-4-methyl-2-undecyl-2-oxazoline.
13. 2-(2-decyl)-2-oxazoline.
14. 2-(2-dodecyl)-2-oxazoline.
15. 4-Methyl-2-(2-dodecyl)-2-oxazoline.
16. 4-Isopropyl-2-(2-dodecyl)-2-oxazoline.
17. 4-t-Butyl-2-(2-dodceyl)-2-oxazoline.
18. 4-Trifluoromethyl-2-(2-dodecyl)-2-oxazoline.
19. 4,4-Dimethyl-2-(2-dodecyl)-2-oxazoline.
20. 4-Methyl-4-isopropyl-2-(2-dodecyl)-2-oxazoline.

21. 4-Methyl-4-t-butyl-2-(2-dodecyl)-2-oxazoline.
22. 4-Methyl-4-trifluoromethyl-2-(2-dodecyl)-2-oxazoline.
23. 4-Hydroxymethyl-4-methyl-2-(2-dodecyl)-2-oxazoline.
- 5 24. 4-[2-(Trimethylacetoxy)ethyl]-4-methyl-2-(2-dodecyl)-2-oxazoline.
25. 2-(2-methyl-2-decyl)-2-oxazoline.
26. 2-(2-methyl-2-dodecyl)-2-oxazoline.
- 10 27. 4-Trifluoromethyl-2-(2-methyl-2-decyl)-2-oxazoline.
28. 4,4-Dimethyl-2-(2-methyl-2-decyl)-2-oxazoline.
29. 4,4-Dimethyl-2-(2-methyl-3-tridecyl)-2-oxazoline.
- 15 30. 2-Nonyl-2-imidazoline.
31. 2-Undecyl-2-imidazoline.
32. 2-Tridecyl-2-imidazoline.
33. 1-Isopropyl-2-pentyl-2-imidazoline.
34. 1-Methyl-2-heptyl-2-imidazoline.
- 20 35. 1-Methyl-2-undecyl-2-imidazoline.
36. 1-Hydroxyethyl-2-octyl-2-imidazoline.
37. 1-[2-(Trimethylacetoxy)ethyl]-2-octyl-2-imidazoline.
38. 1-Isopropyl-2-undecyl-2-imidazoline.
- 25 39. 4-Methyl-2-undecyl-2-imidazoline.
40. 4-Isopropyl-2-undecyl-2-imidazoline.
41. 4-t-Butyl-2-undecyl-2-imidazoline.
42. 4-Trifluoromethyl-2-undecyl-imidazoline.
43. 1,4-Diisopropyl-2-undecyl-2-imidazoline.
- 30 44. 4-t-Butyl-1-isopropyl-2-undecyl-2-imidazoline.
45. 4,4-Dimethyl-2-nonyl-2-imidazoline.
46. 4,4-Dimethyl-2-undecyl-2-imidazoline.
47. 4-Methyl-4-isopropyl-2-undecyl-2-imidazoline.
48. 4-Methyl-4-t-butyl-2-undecyl-2-imidazoline.
- 35 49. 4,4-Diisopropyl-2-undecyl-2-imidazoline.

50. 4-Methyl-4-trifluoromethyl-2-undecyl-2-imidazoline.
51. 4,4-Dimethyl-1-isopropyl-2-pentyl-2-imidazoline.
- 5 52. 4,4-Dimethyl-1-isopropyl-2-undecyl-2-imidazoline.
53. 4,4-Dimethyl-1-isopropyl-2-tridecyl-2-imidazoline.
54. 4,4-Dimethyl-1-isopropyl-2-pentadecyl-2-imidazoline.
- 10 55. 4,4-Dimethyl-1-isopropyl-2-heptadecyl-2-imidazoline.
56. 4,4-Dimethyl-1-n-butyl-2-heptadecyl-2-imidazoline.
- 15 57. 4,4-Dimethyl-1-s-butyl-2-heptadecyl-2-imidazoline.
58. 4-Methyl-1,4-diisopropyl-2-undecyl-2-imidazoline.
59. 4-Methyl-4-t-butyl-1-isopropyl-2-undecyl-2-imidazoline.
- 20 60. 1,4,4-Triisopropyl-2-undecyl-2-imidazoline.
61. 4,4-Dimethyl-1-hydroxyethyl-2-undecyl-2-imidazoline.
62. 4,4-Dimethyl-1-hydroxyethyl-2-heptadecyl-2-imidazoline.
- 25 63. 4,4-Dimethyl-1-[2-(Trimethylacetoxymethyl)]-2-undecyl-2-imidazoline.
64. 4,4-Dimethyl-1-(1-hydroxy-2-methyl-2-propyl)-2-undecyl-2-imidazoline.
- 30 65. 4,4-Dimethyl-1-(1-acetoxy-2-methyl-2-propyl)-2-undecyl-2-imidazoline.
66. 2-(2-decyl)-2-imidazoline.
67. 2-(2-dodecyl)-2-imidazoline.
68. 1-Hydroxyethyl-2-(2-dodecyl)-2-imidazoline.
- 35 69. 1-[2-(Trimethylacetoxymethyl)]-2-(2-dodecyl)-2-imidazoline.

- 2-imidazoline.
70. 1-Isopropyl-2-(2-dodecyl)-2-imidazoline.
71. 4,4-Dimethyl-2-(2-dodecyl)-2-imidazoline.
72. 4,4-Dimethyl-1-isopropyl-2-(2-dodecyl)-2-
5 imidazoline.
73. 2-(1-Dodecen-2-yl)-2-imidazoline.
74. 1-Isopropyl-2-(1-dodecen-2-yl)-2-imidazoline.
75. 4,4-Dimethyl-2-(1-dodecen-2-yl)-2-imidazoline.
76. 4,4-Dimethyl-1-isopropyl-2-(1-dodecen-2-yl)
10 -2-imidazoline.
77. 2-(2-methyl-2-decyl)-2-imidazoline.
78. 2-(2-methyl-2-dodecyl)-2-imidazoline.
79. 1-Hydroxyethyl-2-(2-methyl-2-decyl)-2-
imidazoline.
- 15 80. 1-Trimethylacetoxyethyl-2-(2-methyl-2-decyl)
-2-imidazoline.
81. 4,4-Dimethyl-2-(2-methyl-2-decyl)-2-
imidazoline.
82. 4,4-Dimethyl-1-isopropyl-2-(2-methyl-2-decyl)
20 -2-imidazoline.
83. 4,4-Dimethyl-1-hydroxyethyl-2-(2-methyl-2-
decyl)-2-imidazoline.
84. 4,4-Dimethyl-1-[2-(Trimethylacetoxy)ethyl]-2-
(2-methyl-2-decyl)-2-imidazoline.
- 25 85. 4,4-Dimethyl-1-(1-hydroxy-2-methyl-2-propyl)
-2-undecyl-2-imidazoline.

The following compounds are less stable and, hence,
less desirable for most applications; however, where
stability is not paramount or can be achieved or
30 instability overcome through packaging, increased
concentration, particular derivatives or formulations,
these compounds may be useful:

86. 4-Methyl-2-nonyl-2-oxazoline.
87. 4-Methyl-2-undecyl-2-oxazoline.
- 35 88. 4,4-Dimethyl-2-nonyl-2-oxazoline.

89. 4,4-Dimethyl-2-undecyl-2-oxazoline.
90. 4,4-Dimethyl-2-tridecyl-2-oxazoline.
91. 4-Hydroxymethyl-4-methyl-2-nonyl-2-oxazoline.
92. 4-Hydroxymethyl-4-methyl-2-undecyl-2-oxazoline.
93. 4-Hydroxymethyl-4-ethyl-2-undecyl-2-oxazoline.

Another group of compounds have satisfactory penetration enhancing characteristics and may for some limited purposes be regarded as equivalents; however, these compounds are insufficiently stable for most applications and in most formulations. This group of compounds includes:

94. 2-Pentyl-2-oxazoline.
95. 2-Heptyl-2-oxazoline.
96. 2-Nonyl-2-oxazoline.
97. 2-Undecyl-2-oxazoline.
98. 2-Tridecyl-2-oxazoline.
99. 2-Pentadecyl-2-oxazoline.
100. 2-Heptadecyl-2-oxazoline.

The following 2-oxazolines, encompassed by general formula I of this invention are known in the literature. Compounds 89, 91 and 92 were evaluated for phytotoxicity [Allen and Skoog, Plant Physiol. 26, 611 (1951); C.A. 45: 9790f (1951)]; Compounds 95-100 were evaluated for surface activity [Ishii et al., Yukagaku 7, 70-74(1958); C.A. 55:5993d (1961)]; Compounds 95 and 97 were used to prepare nitrogen containing polymers useful as adhesive and thickeners for water base paints [Litt et al., U.S. Patent No. 3,483,141, Dec. 9, 1969]; Method of preparation for compounds 94, 95, 97 and 100 is disclosed by Litt et al., U.S. Patent No. 3,562,263, Feb. 9, 1971; by Bassiri et al., Polymer Lett. 5,871-9 (1967) and by Levy and Litt, Polymer Lett. 5,881-6 (1967) and for compound 97 by Seeliger and Thier, Justus Liebigs Ann. Chem 698, 158-66 (1966); C.A. 66: 37856x

(1967) and by Seeliger et al., Angew. Chem., Int. Ed. Engl. 5, 875-88(1966); Lactate, citrate and tartrate salts of compounds 88 - 90 were evaluated for their emulsifying and foaming properties [Kimura et al., Yukagaku, 21, 197-200 (1972); C.A. 77: 50538s (1972)] and same salts of compounds 91, 92 and their C₁₃, C₁₅, and C₁₇ homologs were evaluated for surface activity [Kimura et al., Kogyo Kagaku Zasshi, 63,582-5(1960); C.A.: 58, 11583b (1963); Method of preparation for compound 99 disclosed by Litt et al. in U.S. Patent No. 3,681,333, 01 Aug 1972 and compound 99 in a related U.S. Patent No. 3,681,329 01 Aug 1972; Method of preparation for compounds 94, 97 and 100 is disclosed by Witte and Seeliger, Angew. Chem., Int. Ed. Engl. 11,287-8 (1972) and Liebigs Ann. Chem. 996-1009 (1974); Compounds 88-90 and their C₅, C₇, C₁₅ and C₁₇ analogs are disclosed as emulsifiers in polymerization of styrene and butadiene [Frump, U.S. Patent No. 3,886,128; 27 May 1975; C.A. 83: 180219y (1975)]; Organic acid salts of compounds 96-98 were evaluated for their emulsifying and foaming properties [Kimura et al., Yukagaku, 24,869-73 (1975); C.A. 84: 137589c (1976)]; compounds 88-90 and their C₅, C₇, and C₁₅ analogs were disclosed and compound 88 was evaluated for antimicrobial activity [Hunsucker, U.S. Patent No. 4,049,819, 20 Sept. 1977; C.A. 87: 195540c (1977)]; Compound 89 and its C₅ and C₁₇ analogs are disclosed as intermediates in the synthesis of monoacyl glycerols [Hersloef and Gronowitz, Chem. Scr. 22, 230-5 (1983); C.A. 100: 156203n (1984)]; Erskine and Lydon disclose oxazolines with alkyl groups of 7-19 carbon atoms in 2-position and additionally substituted with alkyl or hydroxyalkyl groups with 1-3 carbon atoms in 4 and/or 5 position as surfactants in Iron Blue Pigment Composition suitable for incorporating in transfer or carbon paper inks (U.S. Patent No. 2,893,886, July 7,

1959); Thompson et al. disclose 2-alkyl-4,4-dimethyl-2-oxazoline salts of lauryl or oleyl phosphoric acid partial esters as antistatic agents in lubricating compositions for textiles (U.S. Patent No. 2,976,186, 5 Mar. 21, 1961); Johnson discloses 2-alkyl substituted oxazolines (7-17 carbon atoms), additionally substituted with alkyl or hydroxymethyl groups in 4 position as antifoaming and emulsifying agents in fermentation processes (U.S. Patent No. 2,443,825, June 22, 1948) and 10 finally compounds 88-90, 9 and analogs are mentioned as intermediates in the synthesis of alpha-substituted acrylic acids [Serota et al., J. Org. Chem 46, 4147-4151 (1981)].

The following 2-imidazoline derivatives, 15 encompassed by general formula I of this invention, are known in the literature. Synthesis of compounds 30, 31 and 32, and other lower alkyl analogs is reported by Morrill (U.S. Patent No. 2,508,415, May 23, 1950); Compounds 30 and 31 were prepared in low yield by 20 Clintwood and Emmet-Ried, J. Amer. Chem. Soc. 57,2424, (1953); Compound 31 and its C₁₇ homolog were synthesized by Waldmann and Chwala, Chem. Ber. 74,1763 (1941); French Patent No. 811,423, April 14, 1937; U.S. Patent No. 2,155,877, April 25, 1939; Compound 31 was prepared 25 by Piskov et al.; Khim. Geterotsikl, Soedin., 1112 (1976); C.A. 86,5372h (1977); Bockmuhl and Knoll reported the synthesis of C₁₅ and C₁₇ substituted 2-imidazolines intended to be useful for therapeutic or technical purposes, U.S. Patent No. 1,958,529, May 15, 30 1934; C.A. 28,4539 (1934); Wellman and McCallan have reported 2-heptadecyl-2-imidazoline useful as foliage fungicide; C.A. 40,4470 (1946); Kyrides et al., J. Org. Chem. 12,577 (1947) and Shepard and Shonle, J. Amer. Chem. Soc. 69,2269 (1947) have reported synthesis of 35 compounds 31, 32, 34, 35, and 1-ethyl and 1-pentyl-2-

undecyl-2-imidazolines in low to moderate yields and their bacteriostatic and local anesthetic activity; Mikeska in U.S. Patent No. 2,361,488; C.A. 39,2190 (1945) discloses 2-imidazolines substituted in 2-position with saturated or unsaturated alkyl group with 10-23 carbon atoms in paving composition; Russell describes the use of 2-imidazolines and specifically claims 2-heptadecyl-2-imidazoline in herbicidal composition, U.S. Patent No. 2,514,341, July 4, 1950; Compound 51 was prepared by Harnsberger and Riebsomer, J. Hetero. Chem. 1,188 (1964) and Compounds 51-57 were reported in very low yield by Riebsomer, J. Amer. Chem. Soc. 70,1629 (1948); Compound 31 and its C₅, C₁₀, C₁₂ and C₁₇ analogs as well as compound 39 and its C₁₇ analog were prepared by Sawa, Nippon Kagaku Zasshi, 89,780 (1968; C.A. 70 19983q (1969). Wilson discloses 1-hydroxyalkyl-2-imidazolines and specifically, 1-hydroxyethyl-2-heptadecyl-2-imidazoline, as surface active agents, U.S. Patent No. 2,267,965 (Dec. 30, 1941) and U.S. Patent No. 2,268,273 (Dec. 30, 1941). Tryon reported the preparation of compounds 33, 38 and two higher homologs in very low yield, U.S. Patent No. 2,520,102 (Aug. 22, 1950).


To my knowledge the other compounds are novel.

The use of the compounds of the present invention as penetration enhancers is, however, novel and not predictable from the prior art.

The compounds covered by the general formula I may be prepared by any of the processes known for the preparation of 2-oxazoline derivatives, for example:

1) Heating a nitrile of formula R-CN with an aminoalcohol of the following formula II in presence of cadmium acetate dihydrate or zinc acetate dihydrate at 100-130°C with or without a solvent affords the compounds of this invention:

16




(wherein R, R' and R'' are as defined above) [Witte and Seeliger, *Angew. Chem., Int. Ed. Eng.*, 11, 287-8 (1972); Liebigs *Ann. Chem.* 996-1009 (1974)]. Alternately, an allenic or acetylenic nitrile with an aminoalcohol of formula II on heating gives the compounds of this invention [Fomum et al., *Tet. Lett.* 1101-4 (1975)].

2) A carboxylic acid, R-COOH, is made to react with an aminoalcohol of the formula II with or without solvent at a temperature of from 150 to 250°C with elimination of water [Serota et al., *J. Org. Chem.* 46, 4147-51 (1981); Hersloef and Gronowitz, *Chem. Scr.* 22,230-5 (1983); Frump, *Chem. Rev.* 71, 483-505 (1971); Meyers and Mihelich, *Angew. Chem., Int. Ed. Eng.* 15, 270-281 (1976)]. In addition compounds, which possess an exocyclic double bond on hydrocarbon group R, for example, compounds 20-22, can be prepared according to Serota et al., *J. Org. Chem.*, 46, 4147-51 (1981) from the reaction of 2-alkyl oxazolines with formaldehyde, followed by dehydration. Alternately, aminoalcohol of the formula II may be reacted with an acrylate ester in presence of a catalyst and a polymerization inhibitor, De Benneville and Luskin, U.S. Patent No. 2,831,858 (April 22, 1958); C.A. 52, 16379h (1958); U.S. Patent No. 2,897,192 (July 28, 1959); C.A. 54, 585f (1960); Luskin and De Benneville, *Ger. Patent No.* 1,067,437 (Oct. 22, 1959); C.A. 55, 19960a (1961). In case of unsubstituted aminoalcohols, the resulting amidoalcohols can be cyclodehydrated as under 3.

3) Cyclodehydration of an amidoalcohol of formula III:

17




5 (wherein R, R' and R'' are as defined above) to 2-oxazoline derivative is catalyzed by $\text{WO}_3 \cdot \text{H}_2\text{O}$, $\text{NaWO}_4 \cdot 2\text{H}_2\text{O}$, MoO_2 and SrWO_4 (Litt et al., U.S. Patent No. 3,681,333 and U.S. Patent No. 3,681,329, 01 Aug. 1972) or by silica, alumina, silica-alumina or silica-magnesia
 10 at 200-400°C under reduced pressure [Litt and Levy, U.S. Patent No. 3,562,263, Feb. 9, 1971; Seeliger and Thier, Justus Liebigs Ann. Chem. 698, 158-66 (1966); Seeliger et al., Angew. Chem., Int. Ed. Eng. 5, 875-88 (1966)] or by treatment with SOCl_2 , RSO_2Cl , COCl_2 or $\text{PO}(\text{OR})_2\text{Cl}$ in
 15 order to replace the hydroxyl group by an efficient leaving group that can be eliminated more readily during cyclization [Ishii et al., Yukagaku, 7, 70-4 (1958); C.A. 55, 5993 (1961) and Zioudrou and Schmir, J. Amer. Chem. Soc. 85, 3258 (1963)] or simply on heating at high
 20 temperature with or without a catalytic amount of a strong mineral acid, De Benneville et al., J. Org. Chem., 23, 1355 (1958).

The amidoalcohol of formula III mentioned above may be prepared from carboxylic acid of formula, R-COOH ;
 25 from carboxylic acid chloride of formula, R-COCl or from carboxylic acid ester of the formula, $\text{R-COOR}'''$ (where R''' is an alkyl group) with an aminoalcohol of formula II mentioned above with or without solvent at a temperature from 0°C to 150°C [Wenker, J. Amer. Chem.
 30 Soc. 57, 1079 (1935); D'Alelio and Emmet Reid, J. Amer. Chem. Soc. 59, 111 (1937); Bassiri et al., Polymer Lett 5, 871-9 (1967)].

4) Cyclization of the haloamide of the formula IV:

18

IV



5

(wherein R, R' and R'' are as defined above) with a base such as sodium or potassium hydroxide in aqueous or aqueous alcohol solution or better yet with anhydrous sodium carbonate at an elevated temperature (50°C-250°C) under reduced pressure (0.1mm - 30mm), [Frump, Chem. Rev. 71,483 (1971) and references cited therein; Bassiri, French Pat. 1,477,049, 14 April 1967; Bassiri et al., Polymer Lett. 5, 871-9 (1967);

5) Addition of an epoxide to a nitrile of the formula, R-CN, in concentrated sulfuric acid gives oxazolines of this invention [Oda et al., Bull. Soc. Chem. Japan, 35, 1219 (1962)].

6) Reaction of an iminoester with an aminoalcohol of formula II mentioned above affords the penetration enhancers of this invention [McCasland and Horswill, J. Amer. Chem. Soc., 73, 3744 (1951); Dornow and Theidel, Chem. Ber. 88, 1267 (1955); and British Patent 704,946 (1954); C.A. 49, 10370 (1956)].

7) Reaction of an epoxide with an amidine yields oxazolines of this invention [Lambert and Kristofferson, J. Org. Chem., 30,3938 (1965)].


8) Treatment of a carboxylic acid of the formula, R-COOH or a carboxylic acid chloride of the formula, R-COCl with ethyleneimine, followed by catalytic isomerization of the carboxylic acid amide gives the oxazolines of this invention [Kagiya et al., Polymer Lett., 4, 441-5 (1966); Heine et al., J. Amer. Chem. Soc., 81 2202 (1959); Fanta and Deutsch, J. Org. Chem., 23,72 (1958); Meyers et al., J. Org. Chem., 39,2787 (1974); Fukui et al., Japan 69 22,285 (Sept. 24, 1969);

C.A. 71, 12449p (1969)].

The heterocyclic compounds containing $X = NR_1$ (wherein R_1 is as defined above) covered by the general formula I may be prepared by any one of the classical processes known for the preparation of 2-imidazolines; 5
Ferm and Riebsomer, Chem. Rev. 593 (1954).

For example, treating a diamine of the formula V or its salt 1) with a carboxylic acid of the formula $R-COOH$, its ester, acid chloride, anhydride, amide, 10
thioamide or nitrile derivative followed by ring closure.

V




15

(wherein R , R' and R''_1 are as defined above)


The reaction may be carried out in a solvent such as benzene at 130° - $230^{\circ}C$ with azeotropic removal of 20
water, Riebsomer, J. Amer. Chem. Soc. 70, 1629 (1948); Harnsberger and Riebsomer, J. Hetro. Chem. 1,188 (1964). The monoacyl or diacyl derivatives formed may or may not be isolated and ring closed, for example, in presence of oxides of calcium or magnesium or other dehydrating 25
agents, Chitwood and Ried, J. Amer. Chem. Soc. 57,2424 (1935); Waldman and Chwala, Chem. Ber. 74,1763 (1941); Fr. Patent No. 811,423 (April 14, 1937); C.A. 31, 8550 (1937); Br. Patent No. 479,491 (Feb. 7, 1938); C.A. 32,5002 (1938); U.S. Patent No. 2,155,877, (April 23, 30
1939); and 2,155,878 (April 25, 1939); C.A. 33,5878 (1939), Kyrides and Zienty, U.S. Patent No. 2,404,300 (July 16, 1946); C.A. 40,6101 (1946); Kyrides, U.S. Patent No. 2,404,299 (July 16, 1946); C.A. 41,160 (1946); Kyrides and Zienty, U.S. Patent No. 2,399,601 35
(April 30, 1946); C.A. 40,4180 (1946); Kyrides, U.S.

Patent No. 2,392,326 (Jan. 8, 1946); C.A. 40,1972 (1946); Aspinall, J. Amer. Chem. Soc. 61,3195 (1939); Hill and Aspinall, J. Amer. Chem. Soc. 61,822 (1939); Kyrides, J. Org. Chem. 12,577 (1947); Morrill, U.S. Patent No. 2,508,415 (May 23, 1950); C.A. 45,668 (1951); Piskov et al., Khim. Geterotsikl. Soedin, 1112 (1976); C.A. 86,5372h (1977). The nitrile derivative, R-CN, may be reacted with p-toluene sulfonate salt of diamine of formula V, Oxley and Short, J. Chem. Soc. 497 (1947), Savignac et al., J. Hetero. Chem. 15,897 (1978) or with diamine of formula V in presence of catalytic amount of sulfur, Sawa, Nippon Kagaku Zasshi, 89,780 (1968); C.A. 70,19983q (1969) or in presence of catalytic amount of carbon disulfide at 80° - 190°C for 1 to 48 hours, Hueni, U.S. Patent No. 2,868,802 (Jan. 13, 1959); Fruhstorfer and Muller-Calagan, Ger. Pat. 1,117,588 (Nov. 23, 1961); Hansen, Ger. Pat. 1,670,143 (May 30, 1974);

2) with the imidates of the formula



or amidines of the formula



Bockmuhl and Knoll, U.S. Patent No. 1,958,529 (May 15, 1934); C.A. 28,4539 (1934); Oxley and Short, J. Chem. Soc. 497 (1947); Short and Oxley, Brit. Patent, 614,032 (Dec. 8, 1948); C.A. 43,5049 (1949); I. G. Farbenindustrie A.G., Fr. Pat. 671,362 (Mar. 12, 1929).

The imidazolines may be prepared by treating the imidates mentioned above with aminoalcohol of formula II, Drozdov and Bekhli, J. Gen. Chem. U.S.S.R. 14,480 (1944); C.A. 39,4590 (1945) or by heating a mixture of a
5 carboxylic acid of the formula $R-COOH$ and a 2-imidazolidone at 250-300°C, I. G. Farbenindustrie A.G., Brit. Pat. 492,812 (September 28, 1938); C.A. 33,1761 (1939).

Finally, 2-imidazolines may be prepared by reducing
10 monoacyl derivatives of alpha aminonitriles in presence of a reducing agent, for example, Raney nickel, Hawkins and Biggs, J. Amer. Chem. Soc. 71,2530 (1949); Hawkins, U.S. Patent No. 2,587,043 (Feb. 26, 1952); C.A. 46,9122 (1952).

15 N-substituted 2-imidazolines may be prepared by alkylation of 2-substituted 2-imidazolines with an alkyl halide in presence of a strong base such as sodium hydride in hexamethylphosphotriamide (HMPT) or an organolithium compound, for example, butyl lithium in an
20 inert solvent according to Cognacq, British Patent No. 1,417,174 (Dec. 10, 1975).

The compounds of the present invention may be used as penetration enhancers in the same manner as described in my U.S. Patents 3,989,816; 3,991,203; 4,415,563;
25 4,122,170; 4,316,893; 4,423,040; 4,424,210; 4,444,762 and pending U.S. Application Ser. No. 783,621 filed Sept. 30, 1985, which are hereby incorporated by reference.

The compounds of the present invention are useful
30 as penetration enhancers for a wide range of physiologically active agents, and the compositions disclosed herein are useful for topical and transdermal therapeutic effect of these agents. Typically systemically active agents which may be delivered
35 transdermally are therapeutic agents which are

sufficiently potent such that they can be delivered through the skin or other membranes to the bloodstream in sufficient quantities to produce the desired therapeutic effect. In general this includes agents in
5 all of the major therapeutic areas including, but not limited to, anti-infectives, such as antibiotics and antiviral agents, analgesics, anorexics, anthelmintics, antiarthritics, antiasthma agents, anticonvulsants, antidepressants, antidiabetic agents, antimigraine
10 preparations, antinotion sickness, antinauseants, antineoplastics, antiparkinsonism drugs, antipruritics, antipsychotics, antipyretics, antispasmodics, including gastrointestinal and urinary; anticholinergics, sympathomimetics, xanthine derivatives, cardiovascular
15 preparations including calcium channel blockers, beta-blockers, antiarrhythmics, antihypertensives, diuretics, vasodilators including general, coronary, peripheral and cerebral; central nervous system stimulants, cough and cold preparations, decongestants, diagnostics, hormones,
20 hypnotics, immunosuppressives, muscle relaxants, parasympatholytics, parasympathomimetics, sedatives, tranquilizers and anti-osteoporosis agents.

For topical applications the agents include antibiotics, fungistatic and fungicidal agents,
25 corticosteroids, antiinflammatory agents, antiemetics, antipruritic agents, vasodilators, bronchodilators, expectorants, analgesics, anti-osteoporosis agents, sunscreen compounds, collagen softening agents and other similar compounds. Cosmetic agents, hair and skin dyes,
30 natural and synthetic hormones, perfumes, insect repellents, diagnostic agents and other such compounds may also be advantageously formulated with these penetration enhancers.

Moreover, these penetration enhancers are useful in
35 agriculture in the application of fertilizers, hormones,

growth factors including micronutrients, insecticides, molluscicides, arachides, nematocides, rodenticides, herbicides, and other pesticides to plants, animals and pests. These penetration enhancers are also useful for
5 penetration of micronutrients and chemical hybridization agents in seeds for enhanced plant growth.

Of course, the appropriate dosage levels of all the physiologically active agents, without conjoint use of the penetration enhancing compounds of formula I, are
10 known to those of ordinary skill in the art. These conventional dosage levels correspond to the upper range of dosage levels for compositions including a physiologically active agent and a compound of formula I as a penetration enhancer. However, because the
15 delivery of the active agent is enhanced by compounds of the present invention, dosage levels significantly lower than conventional dosage levels may be used with success. Systemically active agents are used in amounts calculated to achieve and maintain therapeutic blood
20 levels in a human or other animal over the period of time desired. (The term "Animal" as used here encompasses humans as well as other animals, including particularly pets and other domestic animals.) These amounts vary with the potency of each systemically
25 active substance, the amount required for the desired therapeutic or other effect, the rate of elimination or breakdown of the substance by the body once it has entered the bloodstream and the amount of penetration enhancer in the formulation. In accordance with
30 conventional prudent formulating practices, a dosage near the lower end of the useful range of a particular agent is usually employed initially and the dosage increased or decreased as indicated from the observed response, as in the routine procedure of the physician.

35 The present invention contemplates compositions of

compounds of formula I, together with physiologically active agents from 0.05% to 100% of conventional dosage levels. The amount of oxazoline or imidazoline derivative which may be used in the present invention is an effective, non-toxic amount for enhancing percutaneous absorption. Generally, for topical use the amount ranges between 0.01 to about 10 and preferably about 0.1 to 5 percent by weight of the composition. For transdermal enhancement of systemic agents, the amount of penetration enhancer which may be used in the invention varies from about 1 to 100 percent although adequate enhancement of penetration is generally found to occur in the range of about 1 to 30 percent by weight of the formulation to be delivered. For transdermal use, the penetration enhancers disclosed herein may be used in combination with the active agent or may be used separately as a pre-treatment of the skin or other body membranes through which the active agent is intended to be delivered.

Dosage forms for application to the skin or other membranes of humans and animals include creams, lotions, gels, ointments, suppositories, sprays, aerosols, buccal and sublingual tablets and any one of a variety of transdermal devices for use in the continuous administration of systemically active drugs by absorption through the skin, oral mucosa or other membranes, see for example, one or more of U.S. Patent Nos. 3,598,122; 3,598,123; 3,731,683; 3,742,951; 3,814,097; 3,921,636; 3,972,995; 3,993,072; 3,992,073; 3,996,934; 4,031,894; 4,060,084; 4,069,307; r,201,211; 4,230,105; 4,292,299 and 4,292,303. U.S. Patent No. 4,077,407 and the foregoing patents also disclose a variety of specific systemically active agents which may also be useful as in transdermal delivery, which disclosures are hereby incorporated herein by this

reference.

The penetration enhancers of this invention may also be used in admixture with other penetration enhancers disclosed earlier and incorporated herein by
5 reference.

Typical inert carriers which may be included in the foregoing dosage forms include conventional formulating materials such as, for example, water, ethanol, 2-propanol, 1,2-propanediol, 1,3-butanediol, 1,2,3,-
10 propanetriol, propanone, butanone, carboxylic acid esters such as isopropyl myristate, diisopropyl adipate and diisopropyl sebacate, acyclic and cyclic amides including N-methyl pyrrolidone, freons, PEG-200, PEG-400, Polyvinyl pyrrolidone, fragrances, gel producing
15 materials such as "Carbopol", stearyl alcohol, stearic acid, spermaceti, sorbitan monooleate, sorbital, "polysorbates", "Tweens", methyl cellulose, etc.

It will be readily appreciated by those skilled in the art that certain compounds represented by formula I
20 exhibit chirality. However, where no designation of isomers is specified with respect to the compounds of this invention, it is to be understood that all possible stereoisomers are included.

The examples which follow illustrate the penetration enhancers and the compositions of the
25 present invention. However, it is understood that the examples are intended only as illustrative and are not to be construed as in any way limiting to scope of this invention.

30 Example 1

Preparation of 2-undecyl-2-oxazoline

The reaction was carried out under nitrogen atmosphere in a three neck flask equipped with a magnetic stirring bar, reflux condenser, addition funnel
35 and thermometer. 50 ml of 1-butanol and 667 mg (2.5

mmoles) of cadmium acetate dihydrate was introduced and the catalyst was dissolved by slight warming. 18.13 g (100 mmoles) of undecyl cyanide was added and the solution was heated to 125°C. 7.33 g (120 mmoles) of 2-aminoethanol was then added dropwise controlling the evolution of ammonia. At the end of the reaction (ca. 48 hrs.) the solvent was removed under vacuo. The residue was treated with 100 ml of petroleum ether and filtered after keeping for several hours. The filtrate was washed with water, dried over anhydrous magnesium sulfate, concentrated and the residue was distilled 114°C/0.5mm to give 19.83 g (88%) of 2-undecyl-2-oxazoline.

Example 2

Preparation of 2-decyl-2-oxazoline

Undecyl cyanide in Example 1 was substituted with 18.13 g (108.4 mmoles) of undecanenitrile and allowed to react with 7.5 ml (121.3) mmoles of aminoethanol in presence of cadmium acetate dihydrate (667 mg; 2.5 mmoles) in 1-butanol under identical reaction conditions. The reaction mixture was worked up following Example 1 and the residue was distilled at 118-120° / 1.2 mm to give 14.72 g (64.3%) of 2-decyl-2-oxazoline.

Example 3

Preparation of 2-heptadecyl-2-oxazoline

Undecyl cyanide in Example 1 was substituted with 26.55 g (100 mmoles) of heptadecyl cyanide and the reaction was repeated under identical conditions. The residue, after removal of 1-butanol under vacuo, was extracted with 150 ml of toluene at 70°C and filtered. The filtrate was washed with water, dried, concentrated and the residue on slight wash with acetonitrile gave 23.79 g (77%) of 2-heptadecyl-2-oxazoline, m.p. 52-53°C.

Example 4

Preparation of 2-pentyl-2-oxazoline

9.72 g (100 mmoles) of hexanenitrile was substituted for undecyl cyanide in Example 1 and the reaction was repeated with 6.11 g (100 mmoles) of ethanolamine and 549 mg (2.5 mmoles) of zinc acetate dihydrate under identical conditions. At the end of the reaction the product was worked up as before and distilled at 73°C/10mm to give 8.2 g (60%) of 2-pentyl-2-oxazoline.

Example 5

The following compounds are prepared analogously following Example 1 and substituting the undecyl cyanide by the appropriate alkyl cyanide and reacting it with aminoethanol in same molar ratio.

2-heptyl-2-oxazoline

2-nonyl-2-oxazoline

2-tridecyl-2-oxazoline

2-pentadecyl-2-oxazoline

Example 6

Preparation of 4-methyl-2-undecyl-2-oxazoline

10.9 g (60 mmoles) of undecyl cyanide was treated with 5 g (66.6 mmoles) of DL-2-amino-1-propanol in presence of 400 mg (1.5 mmoles) of cadmium acetate dihydrate in 1-butanol as outlined under Example 1. 13.2 g (92%) of product was obtained on distillation at 115-117°C/1-1.5 mm Hg.

Example 7

The following compounds are prepared analogously following Example 6 and substituting undecyl cyanide by 60 mmoles of the appropriate alkyl cyanide.

4-methyl-2-pentyl-2-oxazoline

4-methyl-2-heptyl-2-oxazoline

4-methyl-2-nonyl-2-oxazoline

4-methyl-2-undecyl-2-oxazoline

4-methyl-2-tridecyl-2-oxazoline

4-methyl-2-pentadecyl-2-oxazoline

4-methyl-2-heptadecyl-2-oxazoline

Example 8

The following compounds are prepared analogously following Example 6 and substituting DL-2-amino-1-propanol by 66.6 mmoles of the appropriate aminoalcohol.

4-Trifluoromethyl-2-undecyl-2-oxazoline

4-Isopropyl-2-undecyl-2-oxazoline

4-t-Butyl-2-undecyl-2-oxazoline

10

Example 9

Preparation of 4-ethyl-2-undecyl-2-oxazoline

25 g (137.9 mmoles) of undecyl cyanide was treated with 15.2 ml (165 mmoles) of DL-2-amino-1-butanol in presence of 919 mg (3.54 mmoles) of cadmium acetate dihydrate in 1-butanol as outlined under Example 1. 31.31g (89.6%) of product was obtained on distillation at 124-125°C/1.2-1.4mmHg.

15

Example 10

The following compounds are prepared analogously following Example 10 and substituting undecyl cyanide by 137.9 mmoles of the appropriate alkyl cyanide.

20

4-ethyl-2-pentyl-2-oxazoline

4-ethyl-2-heptyl-2-oxazoline

4-ethyl-2-nonyl-2-oxazoline

25

4-ethyl-2-decyl-2-oxazoline

4-ethyl-2-tridecyl-2-oxazoline

4-ethyl-2-pentadecyl-2-oxazoline

4-ethyl-2-heptadecyl-2-oxazoline

Example 11

30

Preparation of 4,4-dimethyl-2-undecyl-2-oxazoline

64 g (320 mmoles) of dodecanoic acid and 61.1 ml (640 mmoles) of 2-amino-2-methylpropanol was placed in a two neck flask equipped with a vigreux column, distillation condenser and a thermometer. The temperature of the reaction mixture was slowly brought

35

cooling, a 10% alcoholic KOH solution (2 g, 3.6 mmoles) was added and the reflux was continued at 180°C for 4 hours. The excess 2-amino-2-methyl-propanol was distilled at aspirator pressure (86°C/ 18 mm). When the vapor temperature reached 103°C, the distillation was discontinued and the residue was taken in petroleum ether and filtered. The filtrate was washed with dilute KOH, water, dried and concentrated. The oil was distilled at 120°C / 1.2 mmHg to give 70.5 g (87%) of product.

Example 12

Preparation of 4,4-dimethyl-2-pentyl-2-oxazoline

Following the procedure under Example 11, 6.085 g (52.4 mmoles) of hexanoic acid and 10 ml (9.34 g, 104.8 mmoles) of 2-amino-2-methylpropanol was heated to 185°C. Work up and fractional distillation gave 7.2g (81%) of product, b.p. 90-92°C/25 mm Hg.

Example 13

Preparation of 4,4-dimethyl-2-heptadecyl-2-oxazoline

Following example 11, 14.9 g (52.4 mmoles) of octadecanoic acid and 9.34 g (104.8 mmoles) of 2-amino-2-methylpropanol gave 14.1 g (79.7%) of product, b.p. 140-143°C/0.01 mmHg.

Example 14

The following compounds are prepared analogously following the procedure under Example 11 and substituting the dodecanoic acid by the appropriate alkanic acid.

4,4-dimethyl-2-heptyl-2-oxazoline
4,4-dimethyl-2-nonyl-2-oxazoline
4,4-dimethyl-2-tridecyl-2-oxazoline
4,4-dimethyl-2-pentadecyl-2-oxazoline

Example 15

Preparation of 4,4-Dimethyl-2-(1-dodecen-2-yl)-2-oxazoline

4.2 g (141 mmoles) of paraformaldehyde was added to

30

22.5 g (88.8 mmoles) of 4,4-dimethyl-2-undecyl-2-oxazoline (obtained in Example 11) at 90°C. The mixture was stirred at 90°C for 30 minutes and the temperature was raised by 5°C increment every half hour up to 115°C. 5 20 ml of cumene was added and the mixture was refluxed for 2.5 hours at 180°C with removal of water using a Dean-Stark trap. The solution was distilled at 126-129°C/1mm to give 18.2 g of product. This contained 5-10% of starting oxazoline. LPLC purification on 40-60 10 micron silica gel (petroleum ether to 90% petroleum ether/ethyl acetate gradient) gave 16.5 g (70%) of pure product.

Example 16

The following compounds are prepared analogously following Example 15 and substituting the 4,4-dimethyl- 15 2-undecyl-2-oxazoline by equimolar amounts of the corresponding 4-trifluoromethyl and 4-methyl-4-trifluoromethyl derivatives.

4-Trifluoromethyl-2-(1-dodecen-2-yl)-2-oxazoline
20 4-Methyl-4-trifluoromethyl-2-(1-dodecen-2-yl)-2-oxazoline

Example 17

Preparation of 4-hydroxymethyl-4-methyl-2-undecyl-2-oxazoline

25 A mixture of 20.03 g (100 mmoles) of dodecanoic acid and 11.57 g (110 mmoles) of 2-amino-2-methyl-1,3-propanediol in 10 ml of xylene was heated for 30 hours at 185-190°C with azeotropic removal of water. The reaction mixture was taken up in ethyl acetate and was 30 washed with water to remove excess amino alcohol. The organic layer was dried, concentrated and the residue was distilled at 152-155°C/ 1 mmHg to give 22.8 g (84.6%) of 4-hydroxymethyl-4-methyl-2-undecyl-2-oxazoline.

35

Example 18

The following compounds are prepared analogously

following Example 17 and substituting the dodecanoic acid by equimolar amount of the appropriate alkanolic acid.

- 4-hydroxymethyl-4-methyl-2-nonyl-2-oxazoline
- 5 4-hydroxymethyl-4-methyl-2-tridecyl-2-oxazoline
- 4-hydroxymethyl-4-methyl-2-pentadecyl-2-oxazoline
- 4-hydroxymethyl-4-methyl-2-heptadecyl-2-oxazoline

Example 19

10 Preparation of 4-hydroxymethyl-4-ethyl-2-undecyl-2-oxazoline

26 g (130 mmoles) of dodecanoic acid and 31 g (260 mmoles) of 2-amino-2-ethyl-1,3-propanediol were condensed together by heating at 185-190°C for 30 hours. Work up and distillation of the residue at 160-162°C/1 mm Hg gave 33.19 g (90%) of the product.

Example 20

The following compounds are prepared analogously following Example 19 and substituting the dodecanoic acid by equimolar amount of an appropriate alkanolic acid.

- 4-hydroxymethyl-4-ethyl-2-octyl-2-oxazoline
- 4-hydroxymethyl-4-ethyl-2-nonyl-2-oxazoline
- 4-hydroxymethyl-4-ethyl-2-tridecyl-2-oxazoline
- 4-hydroxymethyl-4-ethyl-2-pentadecyl-2-oxazoline
- 25 4-hydroxymethyl-4-ethyl-2-heptadecyl-2-oxazoline

Example 21

Preparation of 2-(2-dodecyl)-2-oxazoline

100 mmoles of 2-cyanododecane is treated with 120 mmoles of 2-aminoethanol in 50 ml of 1-butanol in presence of 2.5 mmoles of cadmium acetate dihydrate as outlined under Example 1 to give 2-(2-dodecyl)-2-oxazoline.

Example 22

The following compounds are prepared analogously following Example 21 and substituting 2-aminoethanol by 120 mmoles of the appropriate 2-aminoalkanol derivative.

4-Methyl-2-(2-dodecyl)-2-oxazoline
4-Isopropyl-2-(2-dodecyl)-2-oxazoline
4-t-Butyl-2-(2-dodecyl)-2-oxazoline
4-Trifluoromethyl-2-(2-dodecyl)-2-oxazoline

5

Example 23

Preparation of 2-(2-Methyl-2-decyl)-2-oxazoline
100 mmoles of 2-cyano-2-methyldodecane is reacted
with 120 mmoles of 2-aminoethanol in 50 ml of 1-butanol
in presence of 2.5 mmoles of cadmium acetate dihydrate
10 as outlined under Example 1 to give 2-(2-methyl-2-
decyl)-2-oxazoline.

Example 24

The following compounds are prepared analogously
following Example 23 and substituting 2-aminoethanol by
15 120 mmoles of the appropriate 2-aminoalkanol derivative.

4-Methyl-2-(2-methyl-2-decyl)-2-oxazoline
4-Isopropyl-2-(2-methyl-2-decyl)-2-oxazoline
4-Trifluormethyl-2-(2-methyl-2-decyl)-2-oxazoline

Example 25

20 Preparation of 4,4-Dimethyl-2-(2-dodecyl)-2-oxazoline
10 g of 4,4-Dimethyl-2-(1-dodecen-2-yl)-2-
oxazoline, obtained in Example 15, was dissolved in 200
ml ethanol and hydrogenated in a Parr apparatus over 1 g
of 10% Pd/C at 50 p.s.i. The catalyst was removed and
25 the filtrate was concentrated to give the product. This
was distilled at 120-122° / 0.8 mm to give 9.68 g
(96.5%) of colorless product.

Example 26

Preparation of 4,4-Dimethyl-2-(2-methyl-3-
30 tridecyl)-2-oxazoline

A solution of 25.34 g (100 mmoles) of 4,4-dimethyl-
2-undecyl-2-oxazoline in 250 ml of dry THF under
nitrogen atmosphere was cooled to -78°C. To this was
added 62.5 ml (100 mmoles) of 1.6 M solution of n-butyl
35 lithium in hexane over a period of 15 minutes and the
solution was further stirred for 2 hours. 18.45 g (150

mmoles) of 2-bromopropane was added at -78°C over a period of 30 minutes and the resulting solution was allowed to warm to room temperature overnight. The solution was poured into 250 ml of saturated ammonium chloride solution and the organic phase was separated. The aqueous phase was extracted with 2 X 100 ml of ether, the organic phases were combined and extracted with 2 X 200 ml of brine. After drying over anhydrous magnesium sulphate, the solution was concentrated and the residue was distilled at reduced pressure. 10.2 g of starting material was recovered. 8.82 g (50% based on recovered starting material) of product distilled at $131-134^{\circ}\text{C}$ / 0.8 mm Hg. 2.98 g (14.8%) of disubstituted product was obtained as a higher boiling fraction.

15

Example 27

Preparation of 2-Undecyl-2-imidazoline

18.32g (100 mmoles) of undecyl cyanide, 8.5ml (127 mmole) of ethylenediamine and 0.5ml of carbon disulfide were mixed and heated in an oil bath at 125°C for 24 hours. The reaction mixture was cooled, treated with dilute hydrochloric acid and treated with charcoal. The light yellow filtrate was extracted with ethyl acetate, the organic extracts dried over magnesium sulfate and concentrated. The residue was Kugelrohr distilled and then recrystallized from toluene. Yield 13.7g (61.1%), m.p. 82°C .

25

Example 28

The following compounds were prepared analogously following Example 27 and substituting the undecyl cyanide by equimolar amount of the appropriate alkyl cyanide.

30

2-Pentyl-2-imidazoline

2-Heptyl-2-imidazoline

2-Nonyl-2-imidazoline

35

2-Tridecyl-2-imidazoline

2-Pentadecyl-2-imidazoline

Example 29

Preparation of 1-Methyl-2-heptyl-2-imidazoline

14.207g (113.46 mmoles) of heptyl cyanide, 10.726g (144.69 mmoles) of N-methylethylenediamine and 0.5ml of carbon disulfide were mixed and heated at 125°C for 24 hours. The solution was cooled, diluted with ethyl acetate and extracted with dilute hydrochloric acid. The acidic solution was basified with sodium hydroxide and extracted with ethyl acetate. The organic extracts were treated with charcoal, filtered, concentrated and Kugelrohr distilled at 105°C/1.2mm to give 19.73g (77.3%) of the product.

Example 30

Preparation of 1-Hydroxyethyl-2-octyl-2-imidazoline

13.02g (93.51 mmoles) of octyl cyanide was treated with 12.327g (118.36 mmoles) of 2-(2-amino ethylamino)-ethanol in presence of 0.5ml of carbon disulfide at 125°C for 24 hrs. and worked up as outlined under Example 29. Distillation of the residue at 167-169°C/0.5mm gave 12.332g (62.7%) of product.

Example 31

Preparation of 1-Isopropyl-2-undecyl-2-imidazoline

18.324g of Undecyl cyanide, 15.12g of N-isopropylethylene-diamine and 0.5ml of carbon disulfide were heated at 125°C for 24 hrs. and worked up as mentioned under Example 29, followed by distillation at 150°C/1.2mm gave 21.93g (82.3%) of the product.

Example 32

The following compounds are prepared analogously following Example 31 and substituting the undecyl cyanide by equimolar amount of the appropriate alkyl cyanide.

- 1-Isopropyl-2-pentyl-2-imidazoline
- 1-Isopropyl-2-heptyl-2-imidazoline
- 1-Isopropyl-2-nonyl-2-imidazoline

1-Isopropyl-2-tridecyl-2-imidazoline

1-Isopropyl-2-pentadecyl-2-imidazoline

Example 33

Preparation of 4-Methyl-2-undecyl-2-imidazoline

5 18.31g (100 mmoles) of undecyl cyanide, 9.3g (125 mmoles) of 1,2-diaminopropane and 0.5ml of carbon disulfide were heated to 125°C for 24 hrs. and then worked up as mentioned under Example 29. Kugelrohr distillation at 163-165°C/1.2-1.4mm Hg gave 17.85g (75%)
10 of product.

Example 34

The following compounds are prepared analogously following Example 33 and substituting the 1,2-diaminopropane by equimolar amount of the appropriately
15 substituted 1,2-diamine.

4-Isopropyl-2-undecyl-2-imidazoline

4-t-Butyl-2-undecyl-2-imidazoline

4-trifluoromethyl-2-undecyl-2-imidazoline

Example 35

20 Preparation of 4,4-Dimethyl-2-undecyl-2-imidazoline

18.31g (100 mmoles) of undecyl cyanide, 11g (125 mmoles) of 1,2-diamino-2-methylpropane and 0.5ml of carbon disulfide were heated at 125°C for 48 hrs. and
25 then worked up as under Example 29. Distillation at reduced pressure gave 19.66g (78%) of the product.

Example 36

The following compounds are prepared analogously following Example 35 and substituting the undecyl
30 cyanide by equimolar amount of the appropriate alkyl cyanide

4,4-Dimethyl-2-pentyl-2-imidazoline

4,4-Dimethyl-2-heptyl-2-imidazoline

4,4-Dimethyl-2-nonyl-2-imidazoline

35 4,4-Dimethyl-2-tridecyl-2-imidazoline

Example 37

Preparation of 4-Methyl-4-t-butyl-2-undecyl-2-imidazoline

15g of 2-cyano-2-decanoylamino-3,3-dimethylbutane (prepared from acylation of aminonitrile obtained from treatment of pinacolone with sodium cyanide and ammonium chloride) in 250ml of 95% ethanol and 70ml of ammonium hydroxide was hydrogenated with T-1 Raney Nickel. The catalyst was filtered off. The filtrate was concentrated and the residue was distilled at reduced pressure to give 7.5g (52%) of the product.

Example 38

The following compounds are prepared analogously following Example 37 and substituting the 2-cyano-2-dodecanoylamino-3,3-dimethylbutane by equimolar amount of the appropriate 2-cyano-2-acylaminoalkane.

4-Methyl-4-isopropyl-2-undecyl-2-imidazoline

4,4-Diisopropyl-2-undecyl-2-imidazoline

4-Methyl-4-trifluoromethyl-2-undecyl-2-imidazoline

20

Example 39

Preparation of 4,4-Dimethyl-1-isopropyl-2-undecyl-2-imidazoline

22.84 g. (100 mmoles) of ethyl laurate and 15.34 g. (118 mmoles) of N¹-isopropyl-2-methyl-1,2-propanediamine is heated at 130-230°C. until approximately 100 mmoles of ethanol is collected. Toluene is then cautiously added and the heating is continued until no more water separates. The solution is acidified, the aqueous layer is separated and basified with NaOH. This is extracted with ethyl acetate, the organic extract is dried and concentrated. The oil is distilled at 150-152°C/1.2mm to give 16.74 g (58%) of product.

Example 40

35 The following compounds are prepared analogously following Example 39 and substituting the ethyl laurate

by equimolar amount of the appropriate carboxylic acid lower alkyl ester.

4,4-Dimethyl-1-isopropyl-2-pentyl-2-imidazoline

4,4-Dimethyl-1-isopropyl-2-heptyl-2-imidazoline

5 4,4-Dimethyl-1-isopropyl-2-nonyl-2-imidazoline

4,4-Dimethyl-1-isopropyl-2-tridecyl-2-imidazoline

4,4-Dimethyl-1-isopropyl-2-pentadecyl-2-imidazoline

4,4-Dimethyl-1-isopropyl-2-heptadecyl-2-imidazoline

Example 41

10 Preparation of 4,4-Dimethyl-1-n-butyl-2-undecyl-2-imidazoline

22 ml (55 mmoles) of a 2.5 M solution of butyl lithium in hexane are added to 12.62g (50 mmoles) of 4,4-dimethyl-2-undecyl-2-imidazoline in 50 ml of anhydrous benzene at a temperature kept at around 20°C. The mixture is then stirred for 2 hours at ambient temperature (15 to 20°C). 8.22g (60 mmoles) of 1-bromobutane is then added dropwise to the reaction mixture, keeping the temperature at around 20°C. The reaction mixture is then stirred at ambient temperature until it is homogenous, after which it is refluxed for 3 hours. After cooling, 50ml of water is added, the mixture is stirred for half hour, decanted and extracted with 100 ml of ether. After drying over magnesium sulfate the solvent is removed in vacuo and the oil is distilled at reduced pressure to give 10.34g (67%) of the product.

Example 42

The following compounds are prepared analogously following Example 41 and substituting 1-bromobutane by an equimolar amount of the appropriate alkyl halide.

1,4,4-Trimethyl-2-undecyl-2-imidazoline

4,4-Dimethyl-1-ethyl-2-undecyl-2-imidazoline

4,4-Dimethyl-1-n-propyl-2-undecyl-2-imidazoline

35 4,4-Dimethyl-1-isopropyl-2-undecyl-2-imidazoline

4,4-Dimethyl-1-s-butyl-2-undecyl-2-imidazoline

Example 43

Preparation of 2-(2-Dodecyl)-2-imidazoline

19.53g (100 mmoles) of 2-cyanododecane, 8.5ml (127 mmoles) of ethylenediamine and 0.5ml of carbon disulfide
5 are reacted according to Example 29 and the reaction mixture is worked up as mentioned therein. Distillation of the residue gives 15.5g (65%) of the product.

Example 44

The following compounds are prepared analogously
10 following Example 43 and substituting the ethylenediamine with an equimolar amount of alkylenediamine:

1-Hydroxyethyl-2-(2-dodecyl)-2-imidazoline
1-Methyl-2-(2-dodecyl)-2-imidazoline
15 1-Isopropyl-2-(2-dodecyl)-2-imidazoline
4,4-Dimethyl-2-(2-dodecyl)-2-imidazoline
4,4-Dimethyl-1-isopropyl-2-(2-dodecyl)-2-imidazoline.

Example 45

Preparation of 2-(2-Methyl-2-decyl)-2-imidazoline
18.32g (100 mmoles) of 2-cyano-2-methyldecane,
8.5ml (127 mmoles) of ethylenediamine and 0.5ml of
5 carbon disulfide are reacted according to Example 29 and
the reaction mixture is worked up as mentioned therein.
Distillation of the residue gives 13.91g (62%) of the
product.

Example 46

10 The following compounds are prepared analogously
following Example 45 and substituting the
ethylenediamine with an equimolar amount of
alkylenediamine.

1-Hydroxyethyl-2-(2-methyl-2-decyl)-2-imidazoline
15 1-Methyl-2-(2-methyl-2-decyl)-2-imidazoline
1-Isopropyl-2-(2-methyl-2-decyl)-2-imidazoline
4,4-Dimethyl-2-(2-methyl-2-decyl)-2-imidazoline
4,4-Dimethyl-1-isopropyl-2-(2-methyl-2-decyl)-2-
imidazoline

20

Example 47

The compounds of Examples 11, 17, 27, 31 and 37
were tested as penetration enhancing agents according to
the procedure below:

25 Skin from female hairless mice, 8-12 weeks old, was
removed from the animals and placed between the donor
and the receptor compartments of diffusion cells, with
normal saline (pH 7.2-7.4) bathing corium. The skin was
incubated at 37°C and the ambient humidity.

100 microliters of the solution containing 1 mg of
30 test drug was applied to the epidermal surface within
the donor compartment. The entire contents from the
4.2ml receptor compartment bathing the corium were
removed for analysis at 5 or 6, 12 and 24 hours
intervals. In each case, the receptor compartment was
35 refilled with 4.2ml of fresh normal saline.

The aliquots removed after 5 or 6, 12 and 24 hours

were analyzed by HPLC using a C-18 reverse phase column. The test solutions used in this experiment contained 1% Hydrocortisone, 2% 1,2-propanediol and 2% penetration enhancer. The control solution did not have penetration enhancer. 1-Dodecylhexahydro-2H-azepin-2-one, Azone (Registered Trademark), described in the U.S. Patents of this inventor as having good penetration enhancing properties, was used for comparison. Another penetration enhancer, 1-Dodecanoylhexahydro-1H-azepine, disclosed in my related U.S. Application Serial Number 783,621, filed on September 30, 1985, was also included for comparison.

The results, as reported in Table 1 below, are average for two cells and clearly show that the compounds of Examples 11, 27, 31 and 37 have far superior penetration enhancing properties as compared to the control, 1-Dodecylhexahydro-2H-azepine-2-one (Azone) and 1-Dodecanoylhexahydro-1H-azepine. The latter two, as evident from this experiment, are equivalent as to their enhancing property.

Table 1

	<u>Penetration Enhancer</u>	<u>% Penetration</u>			
		<u>hrs. 5</u>	<u>6</u>	<u>12</u>	<u>24</u>
1) 1-Dodecanoylhexahydro-					
25	1H-azepine	-	16.2	23.0	34.9
	2) Example 11	-	16.1	28.2	49.1
	3) Example 17	-	8.8	17.3	34.9
	4) 1-Dodecylhexahydro-2H-				
	azepine-2-one, Azone(TM)	-	16.9	22.6	34.4
30	5) -same as above-	7.8	-	17.0	32.8
	6) Example 27	34.8	-	42.1	43.7
	7) Example 31	44.9	-	53.0	54.2
	8) Example 37	35.0	-	47.8	51.8
	9) Control	-	1.3	1.8	2.4

Example 48

The compounds of Examples 11 and 31 were tested as

41

penetration enhancers according to the procedure outlined under Example 47. 1% hydrocortisone in the formulations of Example 47 was substituted by 1% 5-fluorouracil. 1-Dodecylhexahydro-2H-azepin-2-one (Azone - Trademark), was used for comparison. The results are outlined in Table 2 and clearly show that the compound of Example 11 is comparable and the compound of Example 31 is superior to 1-dodecylhexahydro-2H-azepin-2-one.

Table 2

10	Penetration enhancer	% Penetration		
		hrs 6	12	24
	1) 1-Dodecylhexahydro-2H-azepin-2-one	58.4	62.9	64.1
	2) Example 11	59.2	60.3	60.5
15	3) Example 31	74.7	80.2	80.7
	4) Control	8.7	10.4	10.9

Example 49

The following formulation is prepared.

	Solution %
20	Griseofulvin 1
	1-Isopropyl-2-undecyl-2-imidazoline 1
	C ₁₂ - C ₁₅ benzoate 5
	Fragrance 0.1
25	Ethanol 92.9

This formulation is effective in the treatment of fungus infection.

Example 50

An aerosol form of the formulation of Example 35 is prepared by preparing the following mixture:

Formulation	25%
Freon 1	75%

1Freon is 75 / 25 Freon 114 / 12

Example 51

The following cream formulation is prepared:

%

42

	Clindamycin Base	1.0
	Stearyl alcohol, U.S.P.	12.0
	Ethoxylated cholesterol	0.4
	Synthetic spermaceti	7.5
5	Sorbitan monooleate	1.0
	Polysorbate 80, U.S.P.	3.0
	1-Isopropyl-2undecyl- 2-imidazoline	0.9
	Sorbitol solution, U.S.P.	5.5
10	Sodium citrate	0.5
	Chemoderm #844	0.2
	Purified water	68.0

This formulation is effective in the treatment of
acne.

15

Example 52

The following solution formulations are prepared:

	A (%)	B (%)
Clindamycin base	-	1.0
Clindamycin phosphate acid	1.3	-
20 Sodium hydroxide	0.077	-
1 M Hydrochloric acid	-	2.27
Disodium edentate·2H ₂ O	0.003	0.003
Fragrances	0.5	0.5
1-Isopropyl-2-undecyl-		
25 2-imidazoline	1.0	1.0
Purified water	20.0	17.73
Isopropanol	77.12	77.497

These solutions are effective for the treatment of
acne in humans.

Example 53

The following solution formulation is prepared:

		%
	Neomycin sulfate	0.5
5	Lidocaine	0.5
	Hydrocortisone	0.25
	1-Isopropyl-2-undecyl-	
	2-imidazoline	1.0
	Propylene glycol	97.75
10	This solution is effective for the treatment of otitis in domestic animals.	

Example 54

The following sunscreen emulsion is prepared:

		%
15	PABA	2.0
	Benzyl alcohol	0.5
	1-Isopropyl-2-undecyl-	
	2-imidazoline	1.0
	Polyethylene glycol	10.0
20	Isopropyl lanolate	3.0
	Lantrol	1.0
	Acetylated lanolin	0.5
	C ₁₂ - C ₁₅ benzoate	5.0
	Diisopropyl adipate	2.0
25	Cetyl alcohol	1.0
	Veegum	1.0
	Propylene glycol	3.0
	Purified water	70.0

Example 55

30 The following antineoplastic solution is prepared:

	5-fluorouracil	5	%
	1-Isopropyl-2-undecyl-		
	2-imidazoline	1.5	%
	Polyethylene glycol	5	%
35	Purified water	88.5	%

Example 56

The following insect repellent atomizing spray is prepared:

	%
N,N-diethyltoluamide	0.5
5 1-Isopropyl-2-undecyl- 2-imidazoline	0.5
Ethanol	99

Example 57

The following cream formulation may be prepared containing about 0.001 to 1 percent, with preferably 0.1% fluocinolone acetonide:

	%
<u>Oil Phase</u>	
Fluocinolone acetonide	0.1
15 1-Isopropyl-2-undecyl- 2-imidazoline	1.6
Cetyl alcohol	9.3
Stearyl alcohol	1.3
Glyceryl monostearate	3.8
20 <u>Water Phase</u>	
Propylene glycol	10
Sodium dodecyl sulfate	0.1
Deionized water q.s.	100

The steroid is dissolved in the vehicle and added to a stirred, cooling melt of the other ingredients. The preparation is particularly useful for the treatment of inflamed dermatoses by topical application to the affected skin area. The amount and frequency of application is in accordance with standard practice for topical application of this steroid. Penetration of this steroid in the inflamed tissue is enhanced and a therapeutic level is achieved more rapidly and sustained for longer duration than when the steroid is applied in the conventional formulation.

Example 58

The following analgesic gel is prepared:

45

	%
Carbopol 941	1.5
Indomethacin	1
Ethanol	35
5 Diisopropanolamine	1.8
Diisopropyl adipate	5
1-Isopropyl-2-undecyl- 2-imidazoline	2
Water	53.7

10

Example 59

The following cream formulation is prepared:

	%
Isosorbide dinitrate	10
Glycerol monostearate	5.5
15 Polyoxyethylene stearate	4.5
C ₈ -C ₁₈ fatty acid esters of a glycerol ethoxylated with about 7 moles of ethylene oxide	8
1-Isopropyl-2-undecyl 20 2-imidazole	2
Sorbic acid	0.165
Ascorbyl palmitate	0.055
Citric acid	0.1
Na EDTA	0.014
25 Fragrance	0.05
Water	69.616

This formulation is effective in the treatment of
angina.

Example 60

The following skin moisturizing formulation is prepared:

		%
5	Pyrrolidonecarboxylic acid Na	1
	Glycerine	4
	Citric acid	0.03
	Sodium citrate	0.05
	Allantoin	0.1
10	Ethanol, 95%	9
	Oleth-15	1
	Linoleic acid	1
	1-isopropyl-2-undecyl- 2-imidazoline	2
15	Sunscreen agent	0.1
	Water	81.72

Example 61

Examples 49-60 are repeated, except the 1-isopropyl-2-undecyl-2-imidazoline is replaced with an equal amount of each of the following listed compounds, and comparable results are obtained.

- 20 4-trifluoromethyl-2-undecyl-2-oxazoline
 4-Methyl-4-trifluoromethyl-2-undecyl-2-oxazoline
 4,4-Dimethyl-2-(1-dodecen-2-yl)-2-oxazoline
 25 4-t-Butyl-2-(dodecyl)-2-oxazoline
 4,4-Dimethyl-2-(2-dodecyl)-2-oxazoline
 2-(Methyl-2-decyl)-2-oxazoline
 4,4-Dimethyl-2-(2-methyl-2-decyl)-2-oxazoline
 2-Undecyl-2-imidazoline
 30 1-Isopropyl-2-pentyl-2-imidazoline
 1-Methyl-2-heptyl-2-imidazoline
 1-Hydroxyethyl-2-octyl-2-imidazoline
 4-Methyl-2-undecyl-2-imidazoline
 4,4-Dimethyl-2-undecyl-2-imidazoline
 35 4-Methyl-4-t-butyl-2-undecyl-2-imidazoline
 4,4-Dimethyl-1-isopropyl-2-pentyl-2-imidazoline

- 4,4-Dimethyl-1-isopropyl-2-undecyl-2-imidazoline
1-Isopropyl-2-(2-dodecyl)-2-imidazoline
4,4-Dimethyl-2-(2-dodecyl)-2-imidazoline
4,4-Dimethyl-1-isopropyl-2-(2-dodecyl)-2-imidazoline
5 2-(2-Methyl-2-decyl)-2-imidazoline
4,4-Dimethyl-2-(2-methyl-2-decyl)-2-imidazoline
4,4-Dimethyl-1-isopropyl-2-(2-methyl-2-decyl)-2-
imidazoline
1-[2-(Trimethylacetoxylethyl)-2-octyl-2-imidazoline
10 The next preceeding list of compounds, along with
1-isopropyl-2-undecyl-2-imidazoline have been found to
be significantly superior penetration enhancing agents,
both as compared with the prior art and as compared with
the other examples given herein.
15 While particular embodiments of the invention have
been described it will be understood of course that the
invention is not limited thereto since many obvious
modifications can be made and it is intended to include
within this invention any such modifications as will
20 fall within the scope of appended claims.

Industrial Application


This invention is useful in the pharmaceutical and
agricultural industries and in the preparation of
compositions for cosmetic, diagnostic and therapeutic
25 use.

WHAT IS CLAIMED IS:

1. A composition useful for topically administering physiologically active agents through the skin and mucous membranes of humans and animals in a transdermal device or formulation for systemic use or to the skin of humans and animals for localized use comprising:

(a) an effective amount of a physiologically active agent, and

(b) a non-toxic, effective penetrating amount of a penetration enhancing compound of formula I:



wherein: R is a saturated or unsaturated hydrocarbon group with from 5 to 19 carbon atoms; R' and R'' are hydrogen, lower alkyl, trifluoromethyl, lower hydroxyalkyl or lower alkyl ester of lower hydroxyalkyl, with the proviso that both R' and R'' are not lower hydroxyalkyl; X is O or NR₁; R₁ being hydrogen, lower alkyl, lower alkenyl, lower hydroxyalkyl or lower alkyl ester of lower hydroxyalkyl.

2. The composition of Claim 1 wherein R' and R'' are H, the penetration enhancing compound being selected from the group consisting of: 2-(2-dodecyl)-2-oxazoline, 2-(2-methyl-2-decyl)-2-oxazoline, 2-undecyl-2-imidazoline, 1-methyl-2-heptyl-2-imidazoline, 1-isopropyl-2-undecyl-2-imidazoline, 1-hydroxyethyl-2-octyl-2-imidazoline, and 1-[2-(trimethylacetoxymethyl)-2-octyl-2-imidazoline.

3. The composition of Claim 1 wherein R' is hydrogen and R'' is lower alkyl or trifluoromethyl, the penetration enhancing compound being selected from the group consisting of 4-methyl-2-(2-dodecyl)-2-oxazoline, 4-isopropyl-2-(2-dodecyl)-2-oxazoline, 4-trifluoromethyl-2-(2-dodecyl)-2-oxazoline, 4-isopropyl-2-(2-methyl-2-dodecyl)-2-oxazoline, 4-Methyl-2-undecyl-2-imidazoline, 4-isopropyl-2-undecyl-2-imidazoline, 4-t-butyl-2-undecyl-2-imidazoline, 4-trifluoromethyl-2-undecyl-2-imidazoline, 1,4-diisopropyl-2-undecyl-2-imidazoline, 4-methyl-1-isopropyl-2-undecyl-2-imidazoline, 4-methyl-2-(2-dodecyl)-2-imidazoline, and 4-Methyl-2-(2-methyl-2-decyl)-2-imidazoline.
4. The composition of Claim 1 wherein R' and R'' are lower alkyl or trifluoromethyl; the penetration enhancing compound being selected from the group consisting of 4,4-dimethyl-2-undecyl-2-oxazoline, 4-methyl-4-trifluoromethyl-2-undecyl-2-oxazoline, 4,4-dimethyl-2-(1-dodecen-2-yl)-2-oxazoline, 4-methyl-4-trifluoromethyl-2-(1-dodecen-2-yl)-2-oxazoline, 4,4-dimethyl-2-(2-dodecyl)-2-oxazoline, 4,4-dimethyl-2-(2-methyl-2-decyl)-2-oxazoline, 4,4-dimethyl-2-undecyl-2-imidazoline, 4-methyl-4-t-butyl-2-undecyl-2-imidazoline, 4,4-dimethyl-1-isopropyl-2-undecyl-2-imidazoline, 4-methyl-1,4-diisopropyl-2-undecyl-2-imidazoline, 4,4-dimethyl-2-(2-dodecyl)-2-imidazoline, 4,4-dimethyl-1-isopropyl-2-(2-dodecyl)-2-imidazoline, 4,4-dimethyl-2-(2-methyl-2-decyl)-2-imidazoline, 4,4-dimethyl-1-isopropyl-2-(2-methyl-2-decyl)-2-imidazoline.
5. The composition of Claim 1 wherein R' is lower alkyl or trifluoromethyl and X is 0; the penetration enhancing compound being selected from the group consisting of 4-hydroxymethyl-4-methyl-2-

- undecyl-2-oxazoline, 4-hydroxymethyl-4-trifluoromethyl-2-undecyl-2-oxazoline, 4-trimethylacetoxymethyl-4-methyl-2-undecyl-2-oxazoline, 4-hydroxymethyl-4-methyl-2-(2-dodecyl)-2-oxazoline, 4-hydroxymethyl-4-methyl-2-(2-methyl-2-decyl)-2-oxazoline, 4-trimethylacetoxymethyl-4-methyl-2-(2-dodecyl)-2-oxazoline, and 4-trimethylacetoxymethyl-4-methyl-2-(2-methyl-2-decyl)-2-oxazoline.
6. The composition of Claim 1 wherein the penetration enhancement compound comprises one or more compounds selected from the group consisting of 4-methyl-2-nonyl-2-oxazoline, 4-methyl-2-undecyl-2-oxazoline, 4-trifluoromethyl-2-undecyl-2-oxazoline, 4-isopropyl-2-nonyl-2-oxazoline, 4-isopropyl-2-undecyl-2-oxazoline, 4-t-butyl-2-undecyl-2-oxazoline, 4-methyl-4-trifluoromethyl-2-undecyl-2-oxazoline, 4-methyl-4-isopropyl-2-undecyl-2-oxazoline, 4-methyl-4-t-butyl-2-undecyl-2-oxazoline, 4-trifluoromethyl-2-(1-dodecen-2-yl)-2-oxazoline, 4-methyl-4-trifluoromethyl-2-(1-dodecen-2-yl)-2-oxazoline, 4-hydroxymethyl-4-ethyl-2-undecyl-2-oxazoline, 4-hydroxymethyl-4-trifluoromethyl-2-undecyl-2-oxazoline, 4-trimethylacetoxymethyl-4-methyl-2-undecyl-2-oxazoline, 2-(2-decyl)-2-oxazoline, 2-(2-dodecyl)-2-oxazoline, 4-methyl-2-(2-dodecyl)-2-oxazoline, 4-isopropyl-2-(2-dodecyl)-2-oxazoline, 4-t-butyl-2-(2-dodecyl)-2-oxazoline, 4-trifluoromethyl-2-(2-dodecyl)-2-oxazoline, 4,4-dimethyl-2-(2-dodecyl)-2-oxazoline, 4-methyl-4-isopropyl-2-(2-dodecyl)-2-oxazoline, 4-methyl-4-t-butyl-2-(2-dodecyl)-2-oxazoline, 4-methyl-4-trifluoromethyl-2-(2-dodecyl)-2-oxazoline, 4-hydroxymethyl-4-methyl-2-(2-dodecyl)-2-oxazoline, 4-[2-(trimethylacetoxymethyl)-4-methyl-2-(2-dodecyl)-2-oxazoline, 2-(2-methyl-2-decyl)-2-oxazoline, 2-(2-


methyl-2-dodecyl)-2-oxazoline, 4-trifluoromethyl-
2-(2-methyl-2-decyl)-2-oxazoline, 4,4-dimethyl-2-
(2-methyl-2-decyl)-2-oxazoline, 4,4-dimethyl-2-(2-
methyl-3-tridecyl)-2-oxazoline, 1-isopropyl-2-
5 pentyl-2-imidazoline, 1-hydroxyethyl-2-octyl-2-
imidazoline, 1-[2-(trimethylacetoxy)ethyl]-2-octyl-
2-imidazoline, 1-isopropyl-2-undecyl-2-imidazoline,
4-methyl-2-undecyl-2-imidazoline, 4-isopropyl-2-
undecyl-2-imidazoline, 4-t-butyl-2-undecyl-2-
10 imidazoline, 4-trifluoromethyl-2-undecyl-2-
imidazoline, 1,4-diisopropyl-2-undecyl-2-
imidazoline, 4-t-butyl-1-isopropyl-2-undecyl-2-
imidazoline, 4,4-dimethyl-2-nonyl-2-imidazoline,
4,4-dimethyl-2-undecyl-2-imidazoline, 4-methyl-4-
15 isopropyl-2-undecyl-2-imidazoline, 4-methyl-4-t-
butyl-2-undecyl-2-imidazoline, 4,4-diisopropyl-2-
undecyl-2-imidazoline, 4-methyl-4-trifluoromethyl-
2-undecyl-2-imidazoline, 4,4-dimethyl-1-isopropyl-
2-pentyl-2-imidazoline, 4,4-dimethyl-1-isopropyl-2-
20 undecyl-2-imidazoline, 4,4-dimethyl-1-isopropyl-2-
tridecyl-2-imidazoline, 4,4-dimethyl-1-isopropyl-2-
pentadecyl-2-imidazoline, 4,4-dimethyl-1-isopropyl-
2-heptadecyl-2-imidazoline, 4,4-dimethyl-1-n-butyl-
2-heptadecyl-2-imidazoline, 4,4-dimethyl-1-s-butyl-
25 2-heptadecyl-2-imidazoline, 4-methyl-1,4-
diisopropyl-2-undecyl-2-imidazoline, 4-methyl-4-t-
butyl-1-isopropyl-2-undecyl-imidazoline, 1,4,4-
triisopropyl-2-undecyl-2-imidazoline, 4,4-dimethyl-
1-hydroxyethyl-2-undecyl-2-imidazoline, 4,4-
30 dimethyl-1-hydroxyethyl-2-heptadecyl-2-
imidazoline, 4,4-dimethyl-1-[2-
(trimethylacetoxy)ethyl]-2-undecyl-2-imidazoline,
4,4-dimethyl-1-(1-hydroxy-2-methyl-2-propyl)-2-
undecyl-2-imidazoline, 4,4-dimethyl-1-(1-acetoxy-2-
35 methyl-2-propyl)-2-undecyl-2-imidazoline, 2-(2-
decyl)-2-imidazoline, 2-(2-dodecyl)-2-imidazoline,

- 1-hydroxyethyl-2-(2-dodecyl)-2-imidazoline, 1-[2-(trimethylacetoxy)ethyl]-2-(2-dodecyl)-2-imidazoline, 1-isopropyl-2-(2-dodecyl)-2-imidazoline, 4,4-dimethyl-2-(2-dodecyl)-2-imidazoline, 4,4-dimethyl-1-isopropyl-2-(2-dodecyl)-2-imidazoline, 2-(1-dodecen-2-yl)-2-imidazoline, 1-isopropyl-2-(1-dodecen-2-yl)-2-imidazoline, 4,4-dimethyl-2-(1-dodecen-2-yl)-2-imidazoline, 4,4-dimethyl-1-isopropyl-2-(1-dodecen-2-yl)-2-imidazoline, 2-(2-methyl-2-decyl)-2-imidazoline, 2-(2-methyl-2-dodecyl)-2-imidazoline, 1-hydroxyethyl-2-(2-methyl-2-decyl)-2-imidazoline, 1-trimethylacetoxyethyl-2-(2-methyl-2-decyl)-2-imidazoline, 4,4-dimethyl-2-(2-methyl-2-decyl)-2-imidazoline, 4,4-dimethyl-1-isopropyl-2-(2-methyl-2-decyl)-2-imidazoline, 4,4-dimethyl-1-hydroxyethyl-2-(2-methyl-2-decyl)-2-imidazoline, 4,4-dimethyl-1-[2-(trimethylacetoxy)ethyl]-2-(2-methyl-2-decyl)-2-imidazoline, and 4,4-dimethyl-1-(1-hydroxy-2-methyl-2-propyl)-2-undecyl-2-imidazoline.
7. The composition of Claim 1 wherein the physiological agent is an antibiotic.
8. The composition of Claim 7 wherein the antibiotic comprises one or more compounds selected from the group consisting of lincomycin, clindamycin, erythromycin and pharmaceutically useful salts thereof.
9. The composition of Claim 1 wherein the physiologically active agent is a steroid.
10. The composition of Claim 1 wherein the physiologically active agent is an antifungal agent.
11. The composition of Claim 1 wherein the physiologically active agent is iododeoxyuridine.
12. The composition of Claim 1 wherein the

physiologically active agent is 5-fluorouracil.

13. The composition of Claim 1 wherein the physiologically active agent is an anti-inflammatory analgesic active agent selected from the group consisting of indomethacin, diclofenac, ketoprofen, ibuprofen, fenamic acids and pharmaceutically acceptable salts thereof.
14. The composition of Claim 1 wherein the physiologically active agent is bronchodilator or metaproternol.
15. The composition of Claim 1 wherein the physiologically active agent is an antipruritic agent.
16. The composition of Claim 1 wherein the physiologically active agent is clonidine.
17. The composition of Claim 1 wherein the physiologically active agent is a calcium channel blocker selected from the group consisting of nifepidine, verapamil, diltiazem and pharmaceutically acceptable salts thereof.
18. The composition of Claim 1 wherein the physiologically active agent is a vasodilator selected from the group consisting of nitroglycerine, isosorbide dinitrate and pentaerythritol tetranitrate.
19. The composition of claim 1 wherein the penetration enhancing compound consists of one or more compounds selected from the group consisting of: 4-trifluoromethyl-2-undecyl-2-oxazoline, 4-Methyl-4-trifluoromethyl-2-undecyl-2-oxazoline, 4,4-Dimethyl-2-(1-dodecen-2-yl)-2-oxazoline, 4-t-Butyl-2-(dodecyl)-2-oxazoline, 4,4-Dimethyl-2-(2-dodecyl)-2-oxazoline, 2-(2-Methyl-2-decyl)-2-oxazoline, 4,4-Dimethyl-2-(2-methyl-2-decyl)-2-oxazoline, 2-Undecyl-2-imidazoline, 1-Isopropyl-2-pentyl-2-imidazoline, 1-Methyl-2-heptyl-2-imid-

- azoline, 1-Hydroxyethyl-2-octyl-2-imidazoline, 4-Methyl-2-undecyl-2-imidazoline, 4,4-Dimethyl-2-undecyl-2-imidazoline, 4-Methyl-4-t-butyl-2-undecyl-2-imidazoline, 4,4-Dimethyl-1-isopropyl-2-pentyl-2-imidazoline, 4,4-Dimethyl-1-isopropyl-2-undecyl-2-imidazoline, 1-Isopropyl-2-(2-dodecyl)-2-imidazoline, 4,4-Dimethyl-2-(2-dodecyl)-2-imidazoline, 4,4-Dimethyl-1-isopropyl-2-(2-dodecyl)-2-imidazoline, 2-(2-Methyl-2-decyl)-2-imidazoline, 4,4-Dimethyl-2-(2-methyl-2-decyl)-2-imidazoline, 4,4-Dimethyl-1-isopropyl-2-(2-methyl-2-decyl)-2-imidazoline, 1-[2-(Trimethylacetoxy)ethyl]-2-octyl-2-imidazoline, and 1-isopropyl-2-undecyl-2-imidazoline.
20. A method for topically administering physiologically active agents through the skin and mucous membranes of humans and animals in a transdermal device or formulation for systemic use or to the skin of humans and animals for localized use comprising applying to such skin or membrane a mixture of said physiologically active agent and a non-toxic, effective penetrating amount of penetration enhancing compound having the structural formula I:



- wherein: R is a saturated or unsaturated hydrocarbon group with from 5 to 19 carbon atoms; R' and R'' are hydrogen, lower alkyl, trifluoromethyl, lower hydroxyalkyl or lower alkyl ester of lower hydroxyalkyl, with the proviso that both R' and R'' are not lower hydroxyalkyl; X is O or NR₁; R₁ being hydrogen, lower alkyl, lower alkenyl, lower hydroxyalkyl or lower alkyl ester of lower

hydroxyalkyl.

21. The method of Claim 20 wherein R' and R" of formula I are H, the penetration enhancing compound being selected from the group consisting of: 2-(2-dodecyl)-2-oxazoline, 2-(2-methyl-2-decyl)-2-oxazoline, 2-undecyl-2-imidazoline, 1-methyl-2-heptyl-2-imidazoline, 1-isopropyl-2-undecyl-2-imidazoline, 1-hydroxyethyl-2-octyl-2-imidazoline, and 1-[2-(trimethylacetoxymethyl)-2-octyl-2-imidazoline.
22. The method of Claim 20 wherein R' of formula I is hydrogen and R" of formula I is lower alkyl or trifluoromethyl, the penetration enhancing compound being selected from the group consisting of 4-methyl-2-(2-dodecyl)-2-oxazoline, 4-isopropyl-2-(2-dodecyl)-2-oxazoline, 4-trifluoromethyl-2-(2-dodecyl)-2-oxazoline, 4-isopropyl-2-(2-methyl-2-dodecyl)-2-oxazoline, 4-Methyl-2-undecyl-2-imidazoline, 4-isopropyl-2-undecyl-2-imidazoline, 4-t-butyl-2-undecyl-2-imidazoline, 4-trifluoromethyl-2-undecyl-2-imidazoline, 1,4-diisopropyl-2-undecyl-2-imidazoline, 4-methyl-1-isopropyl-2-undecyl-2-imidazoline, 4-methyl-2-(2-dodecyl)-2-imidazoline, and 4-Methyl-2-(2-methyl-2-decyl)-2-imidazoline.
23. The method of Claim 20 wherein R' and R" of formula I are lower alkyl or trifluoromethyl; the penetration enhancing compound being selected from the group consisting of 4,4-dimethyl-2-undecyl-2-oxazoline, 4-methyl-4-trifluoromethyl-2-undecyl-2-oxazoline, 4,4-dimethyl-2-(1-dodecen-2-yl)-2-oxazoline, 4-methyl-4-trifluoromethyl-2-(1-dodecen-2-yl)-2-oxazoline, 4,4-dimethyl-2-(2-dodecyl)-2-oxazoline, 4,4-dimethyl-2-(2-methyl-2-decyl)-2-oxazoline, 4,4-dimethyl-2-undecyl-2-imidazoline, 4-methyl-4-t-butyl-2-undecyl-2-imidazoline, 4,4-

dimethyl-1-isopropyl-2-undecyl-2-imidazoline, 4-methyl-1,4-diisopropyl-2-undecyl-2-imidazoline, 4,4-dimethyl-2-(2-dodecyl)-2-imidazoline, 4,4-dimethyl-1-isopropyl-2-(2-dodecyl)-2-imidazoline, 5 4,4-dimethyl-2-(2-methyl-2-decyl)-2-imidazoline, 4,4-dimethyl-1-isopropyl-2-(2-methyl-2-decyl)-2-imidazoline.

24. The method of Claim 20 wherein R' of formula I is lower alkyl or trifluoromethyl and X of formula I is 0; the penetration enhancing compound being 10 selected from the group consisting of 4-hydroxymethyl-4-methyl-2-undecyl-2-oxazoline, 4-hydroxymethyl-4-trifluoromethyl-2-undecyl-2-oxazoline, 4-trimethylacetoxymethyl-4-methyl-2-undecyl-2-oxazoline, 4-hydroxymethyl-4-methyl-2-(2-dodecyl)-2-oxazoline, 4-hydroxymethyl-4-methyl-2-(2-methyl-2-decyl)-2-oxazoline, 4-trimethylacetoxymethyl-4-methyl-2-(2-dodecyl)-2-oxazoline, and 4-trimethylacetoxymethyl-4-methyl-2-(2-methyl-2-decyl)-2-oxazoline. 15 20

25. The method of Claim 20 wherein the penetration enhancement compound comprises one or more compounds selected from the group consisting of 4-methyl-2-nonyl-2-oxazoline, 4-methyl-2-undecyl-2-oxazoline, 4-trifluoromethyl-2-undecyl-2-oxazoline, 25 4-isopropyl-2-nonyl-2-oxazoline, 4-isopropyl-2-undecyl-2-oxazoline, 4-t-butyl-2-undecyl-2-oxazoline, 4-methyl-4-trifluoromethyl-2-undecyl-2-oxazoline, 4-methyl-4-isopropyl-2-undecyl-2-oxazoline, 4-methyl-4-t-butyl-2-undecyl-2-oxazoline, 4-trifluoromethyl-2-(1-dodecen-2-yl)-2-oxazoline, 4-methyl-4-trifluoromethyl-2-(1-dodecen-2-yl)-2-oxazoline, 4-hydroxymethyl-4-ethyl-2-undecyl-2-oxazoline, 4-hydroxymethyl-4-trifluoromethyl-2-undecyl-2-oxazoline, 4-trimethylacetoxymethyl-4-methyl-2-undecyl-2- 30 35

oxazoline, 2-(2-decyl)-2-oxazoline, 2-(2-dodecyl)-
2-oxazoline, 4-methyl-2-(2-dodecyl)-2-oxazoline, 4-
isopropyl-2-(2-dodecyl)-2-oxazoline, 4-t-butyl-2-
(2-dodecyl)-2-oxazoline, 4-trifluoromethyl-2-(2-
5 dodecyl)-2-oxazoline, 4,4-dimethyl-2-(2-dodecyl)-2-
oxazoline, 4-methyl-4-isopropyl-2-(2-dodecyl)-2-
oxazoline, 4-methyl-4-t-butyl-2-(2-dodecyl)-2-
oxazoline, 4-methyl-4-trifluoromethyl-2-(2-
dodecyl)-2-oxazoline, 4-hydroxymethyl-4-methyl-2-
10 (2-dodecyl)-2-oxazoline, 4-[2-(
trimethylacetoxy)ethyl]-4-methyl-2-(2-dodecyl)-2-
oxazoline, 2-(2-methyl-2-decyl)-2-oxazoline, 2-(2-
methyl)-2-dodecyl)-2-oxazoline, 4-trifluoromethyl-
2-(2-methyl-2-decyl)-2-oxazoline, 4,4-dimethyl-2-
15 (2-methyl-2-decyl)-2-oxazoline, 4,4-dimethyl-2-(2-
methyl-3-tridecyl)-2-oxazoline, 1-isopropyl-2-
pentyl-2-imidazoline, 1-hydroxyethyl-2-octyl-2-
imidazoline, 1-[2-(trimethylacetoxy)ethyl]-2-octyl-
2-imidazoline, 1-isopropyl-2-undecyl-2-imidazoline,
20 4-methyl-2-undecyl-2-imidazoline, 4-isopropyl-2-
undecyl-2-imidazoline, 4-t-butyl-2-undecyl-2-
imidazoline, 4-trifluoromethyl-2-undecyl-2-
imidazoline, 1,4-diisopropyl-2-undecyl-2-
imidazoline, 4-t-butyl-1-isopropyl-2-undecyl-2-
25 imidazoline, 4,4-dimethyl-2-nonyl-2-imidazoline,
4,4-dimethyl-2-undecyl-2-imidazoline, 4-methyl-4-
isopropyl-2-undecyl-2-imidazoline, 4-methyl-4-t-
butyl-2-undecyl-2-imidazoline, 4,4-diisopropyl-2-
undecyl-2-imidazoline, 4-methyl-4-trifluoromethyl-
30 2-undecyl-2-imidazoline, 4,4-dimethyl-1-isopropyl-
2-pentyl-2-imidazoline, 4,4-dimethyl-1-isopropyl-2-
undecyl-2-imidazoline, 4,4-dimethyl-1-isopropyl-2-
tridecyl-2-imidazoline, 4,4-dimethyl-1-isopropyl-2-
pentadecyl-2-imidazoline, 4,4-dimethyl-1-isopropyl-
35 2-heptadecyl-2-imidazoline, 4,4-dimethyl-1-n-butyl-
2-heptadecyl-2-imidazoline, 4,4-dimethyl-1-s-butyl-

- 2-heptadecyl-2-imidazoline, 4-methyl-1,4-diisopropyl-2-undecyl-2-imidazoline, 4-methyl-4-
butyl-1-isopropyl-2-undecyl-imidazoline, 1,4,4-
triisopropyl-2-undecyl-2-imidazoline, 4,4-dimethyl-
5 1-hydroxyethyl-2-undecyl-2-imidazoline, 4,4-
dimethyl-1-hydroxyethyl-2-heptadecyl-2-
imidazoline, 4,4-dimethyl-1-[2-
(trimethylacetoxy)ethyl]-2-undecyl-2-imidazoline,
4,4-dimethyl-1-(1-hydroxy-2-methyl-2-propyl)-2-
10 undecyl-2-imidazoline, 4,4-dimethyl-1-(1-acetoxy-2-
methyl-2-propyl)-2-undecyl-2-imidazoline, 2-(2-
decyl)-2-imidazoline, 2-(2-dodecyl)-2-imidazoline,
1-hydroxyethyl-2-(2-dodecyl)-2-imidazoline, 1-[2-
(trimethylacetoxy)ethyl]-2-(2-dodecyl)-2-
15 imidazoline, 1-isopropyl-2-(2-dodecyl)-2-
imidazoline, 4,4-dimethyl-2-(2-dodecyl-2-
imidazoline, 4,4-dimethyl-1-isopropyl-2-(2-
dodecyl)-2-imidazoline, 2-(1-dodecen-2-yl)-2-
imidazoline, 1-isopropyl-2-(1-dodecen-2-yl)-2-
20 imidazoline, 4,4-dimethyl-2-(1-dodecen-2-yl)-2-
imidazoline, 4,4-dimethyl-1-isopropyl-2-(1-dodecen-
2-yl)-2-imidazoline, 2-(2-methyl-2-decyl)-2-
imidazoline, 2-(2-methyl-2-dodecyl)-2-imidazoline,
1-hydroxyethyl-2-(2-methyl-2-decyl)-2-imidazoline,
25 1-trimethylacetoxyethyl-2-(2-methyl-2-decyl)-2-
imidazoline, 4,4-dimethyl-2-(2-methyl-2-decyl)-2-
imidazoline, 4,4-dimethyl-1-isopropyl-2-(2-methyl-
2-decyl)-2-imidazoline, 4,4-dimethyl-1-
hydroxyethyl-2-(2-methyl-2-decyl)-2-imidazoline,
30 4,4-dimethyl-1-[2-(trimethylacetoxy)ethyl]-2-(2-
methyl-2-decyl)-2-imidazoline, and 4,4-dimethyl-1-
(1-hydroxy-2-methyl-2-propyl)-2-undecyl-2-
imidazoline.
26. The method of Claim 20 wherein the penetration
35 enhancing agent consists essentially of one or more
compounds selected from the group consisting of:

4-trifluoromethyl-2-undecyl-2-oxazoline, 4-Methyl-
4-trifluoromethyl-2-undecyl-2-oxazoline, 4,4-
Dimethyl-2-(1-dodecen-2-yl)-2-oxazoline, 4-t-
Butyl-2-(2-dodecyl)-2-oxazoline, 4,4-Dimethyl-2-(2-
5 dodecyl)-2-oxazoline, 2-(2-Methyl-2-decyl)-2-
oxazoline, 4,4-Dimethyl-2-(2-methyl-2-decyl)-2-
oxazoline, 2-Undecyl-2-imidazoline, 1-Isopropyl-2-
pentyl-2-imidazoline, 1-Methyl-2-heptyl-2-imid-
azoline, 1-Hydroxyethyl-2-octyl-2-imidazoline, 4-
10 Methyl-2-undecyl-2-imidazoline, 4,4-Dimethyl-2-
undecyl-2-imidazoline, 4-Methyl-4-t-butyl-2-
undecyl-2-imidazoline, 4,4-Dimethyl-1-isopropyl-2-
pentyl-2-imidazoline, 4,4-Dimethyl-1-isopropyl-2-
undecyl-2-imidazoline, 1-Isopropyl-2-(2-dodecyl)-2-
15 imidazoline, 4,4-Dimethyl-2-(2-dodecyl)-2-imid-
azoline, 4,4-Dimethyl-1-isopropyl-2-(2-dodecyl)-2-
imidazoline, 2-(2-Methyl-2-decyl)-2-imidazoline,
4,4-Dimethyl-2-(2-methyl-2-decyl)-2-imidazoline,
4,4-Dimethyl-1-isopropyl-2-(2-methyl-2-decyl)-2-
20 imidazoline, 1-[2-(Trimethylacetoxy)ethyl]-2-octyl-
2-imidazoline, and 1-isopropyl-2-undecyl-2-
imidazoline.


éch.: 1/1 

FIG. 1






FIG. 3

FIG. 2



INTERNATIONAL SEARCH REPORT

International Application No PCT/US 87/02846

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁴ : A 61 K 47/00														
II. FIELDS SEARCHED <div style="text-align: right; padding-right: 50px;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border: none;"> <tr> <td style="width: 20%; border: none;">Classification System</td> <td style="border: none;">Classification Symbols</td> </tr> <tr> <td style="border: none; padding-top: 10px;">IPC⁴</td> <td style="border: none; padding-top: 10px;">A 61 K</td> </tr> </table> <p style="text-align: center; padding-top: 10px;">Documentation Searched other than Minimum Documentation to the extent that such Documents are Included in the Fields Searched ⁸</p>			Classification System	Classification Symbols	IPC ⁴	A 61 K								
Classification System	Classification Symbols													
IPC ⁴	A 61 K													
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%; padding: 5px;">Category ¹⁰</th> <th style="width: 60%; padding: 5px;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 30%; padding: 5px;">Relevant to Claim No. ¹³</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X,Y</td> <td style="padding: 5px;">GB, A, 1161671 (FINE ORGANICS) 20 August 1969 see page 1, lines 13-27; page 2, lines 54-61; claims</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-19</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X,Y</td> <td style="padding: 5px;">EP, A, 0189861 (SHOWA DENKO K.K.) 6 August 1986 see page 5, line 9 - page 6, line 12; page 8, line 14 - page 9, line 20; claims</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-19</td> </tr> <tr> <td colspan="3" style="text-align: center; padding: 10px;">-----</td> </tr> </tbody> </table>			Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X,Y	GB, A, 1161671 (FINE ORGANICS) 20 August 1969 see page 1, lines 13-27; page 2, lines 54-61; claims	1-19	X,Y	EP, A, 0189861 (SHOWA DENKO K.K.) 6 August 1986 see page 5, line 9 - page 6, line 12; page 8, line 14 - page 9, line 20; claims	1-19	-----		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³												
X,Y	GB, A, 1161671 (FINE ORGANICS) 20 August 1969 see page 1, lines 13-27; page 2, lines 54-61; claims	1-19												
X,Y	EP, A, 0189861 (SHOWA DENKO K.K.) 6 August 1986 see page 5, line 9 - page 6, line 12; page 8, line 14 - page 9, line 20; claims	1-19												

<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"G" document member of the same patent family</p> </div> </div>														
IV. CERTIFICATION <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; vertical-align: top;"> Date of the Actual Completion of the International Search <div style="text-align: center; padding-top: 10px;">22nd February 1988</div> International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div> </td> <td style="width: 50%; border: none; vertical-align: top;"> Date of Mailing of this International Search Report <div style="text-align: center; padding-top: 10px;">07 APR 1988</div> <div style="text-align: center;"> Signature of Authorized Officer P.C.G. VAN DER PUTTEN </div> </td> </tr> </table>			Date of the Actual Completion of the International Search <div style="text-align: center; padding-top: 10px;">22nd February 1988</div> International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Date of Mailing of this International Search Report <div style="text-align: center; padding-top: 10px;">07 APR 1988</div> <div style="text-align: center;"> Signature of Authorized Officer P.C.G. VAN DER PUTTEN </div>										
Date of the Actual Completion of the International Search <div style="text-align: center; padding-top: 10px;">22nd February 1988</div> International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Date of Mailing of this International Search Report <div style="text-align: center; padding-top: 10px;">07 APR 1988</div> <div style="text-align: center;"> Signature of Authorized Officer P.C.G. VAN DER PUTTEN </div>													

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim number. ^{*} because they relate to subject matter not required to be searched by this Authority, namely:

*) 20-26 See PCT-Rule 39.1 (iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods

2. ☐ Claim numbers because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
☐ No protest accompanied the payment of additional search fees.

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.

US 8702846

SA 20097

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on 14/03/88
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB-A- 1161671	20-08-69	GB-A- 1153717	29-05-69
		DE-A, B, C 1533131	04-12-69
<hr/>			
EP-A- 0189861	06-08-86	JP-A- 61172830	04-08-86
		JP-A- 61254532	12-11-86
		JP-A- 61260026	18-11-86
		JP-A- 61260027	18-11-86
		JP-A- 61268631	28-11-86
		JP-A- 61268632	28-11-86
		JP-A- 62061929	18-03-87
<hr/>			